Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 2 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 PROTOCOL AGREEMENT  
 
I have read the protocol specified below. In my formal capacity as Investigator, my duties 
include ensuring the safety of the study subjects enrolled under my supervision and providing the 
Sponsor -Investigator with complete and timely information, as outlined in the protocol.  It is 
understood that all information pertaining to the study will be held strictly confidential and that 
this confidentiality requirement applies to all study staff at this site. Furthermore, on behalf of 
the study staff and myself, I agree to maintain the procedures required to carry out the study in 
accordance with accepted GCP principles and to abide by the terms of this protocol.  
 
Protocol Number:   TEACH -IP-15 
 
Protocol Title:  TEACH Trial: Testing the Effect of A dding CHronic Azithromycin to Inhaled 
Tobramycin. A randomized, placebo-controlled, double -blinded trial of azithromycin 500mg 
thrice weekly in combination with inhaled tobramycin 
 
Protocol Date:  June 11, 2018 
 
   
Investigator Signature   Date  
 
Print Name and Title  
Site #    
Site Name   
Address  
  
  
  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 3 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 TABLE OF CONTENTS  
 
1 BACKGROUND  ..........................................................................................................................................................15  
2 STUDY RATIONALE  ...................................................................................................................................................20  
2.1 RISK / BENEFIT ASSESSMENT  ................................ ................................ ................................ ................................ ......21 
3 STUDY OBJECTIVES ...................................................................................................................................................21  
3.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ................................ .................. 21 
3.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ ................................ ............ 21 
4 STUDY DESIGN  ..........................................................................................................................................................22  
4.1 STUDY OVERVIEW  ................................ ................................ ................................ ................................ ..................... 22 
5 CRITERIA FOR EVALUAT ION ....................................................................................................................................23  
5.1 PRIMARY ENDPOINT  ................................ ................................ ................................ ................................ .................. 23 
5.2 SECONDARY ENDPOINTS ................................ ................................ ................................ ................................ ............. 23 
6 SUBJECT SELECTION  .................................................................................................................................................24  
6.1 STUDY POPULATION  ................................ ................................ ................................ ................................ .................. 24 
6.2 INCLUSION CRITERIA  ................................ ................................ ................................ ................................ .................. 24 
6.3 EXCLUSION CRITERIA  ................................ ................................ ................................ ................................ ................. 25 
6.4 STUDY SPECIFIC TOLERANCE FOR INCLUSION /EXCLUSION CRITERIA  ................................ ................................ .................. 26 
6.5 SCREEN FAIL CRITERIA  ................................ ................................ ................................ ................................ ............... 26 
7 CONCURRENT MEDICATIO NS..................................................................................................................................26  
7.1 ALLOWED MEDICATIONS AND TREATMENTS  ................................ ................................ ................................ ................. 27 
7.2 CONDITIONALLY ALLOWED MEDICATIONS AND TREATMENTS  ................................ ................................ .......................... 27 
7.3 PROHIBITED MEDICATIONS AND TREATMENTS  ................................ ................................ ................................ .............. 28 
7.4 CHANGE IN MEDICATIONS OR THERAPIES  ................................ ................................ ................................ ..................... 28 
8 STUDY TREATMENTS ................................................................................................................................................28  
8.1 RANDOMIZATION  ................................ ................................ ................................ ................................ ...................... 28 
8.2 BLINDING  ................................ ................................ ................................ ................................ ................................ .29 
8.3 UNBLINDING PROCEDURES  ................................ ................................ ................................ ................................ ......... 29 
8.4 FORMULATION OF TEST AND CONTROL PRODUCTS  ................................ ................................ ................................ ........ 29 
8.5 SUPPLY OF STUDY DRUG TO THE SITE................................ ................................ ................................ ........................... 30 
8.6 DOSE MODIFICATIONS  ................................ ................................ ................................ ................................ ............... 31 
8.7 STUDY DRUG ACCOUNTABILITY  ................................ ................................ ................................ ......................... 31 
8.8 MEASURES OF TR EAT M ENT  COMPLIANCE  ................................ ................................ ................................ .......... 31 
8.9 STANDARD OF CAR E TREATMENT WITH TISP  ................................ ................................ ................................ ....32 
9 STUDY PROCEDURES AND  GUIDELINES  .................................................................................................................32  
9.1 CLINICAL ASSESSMENTS  ................................ ................................ ................................ ................................ ......32 
9.2 CLINICAL LABORATORY MEASUREMENTS ................................ ................................ ................................ .......... 35 
10 EVALUATIONS BY VISIT ............................................................................................................................................35  
10.1 VISIT 1 – DAY -14................................ ................................ ................................ ................................ ............ 35 
10.2 VISIT 2 - DAY 0 (VISIT WINDOW -2/ +4  DAYS ) ................................ ................................ ................................ 36 
10.3 VISIT 3 – DAY 28 (VISIT WINDOW -2/+4  DAYS ), WEEK 4 ................................ ................................ .............. 36 
10.4 VISIT 4 – DAY 56 (VISIT WINDOW +/- 4 DAYS), OPEN-LABEL WEEK 4 ................................ ................................ .37 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 4 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 10.5 VISIT  5 - DAY 84 (VISIT WINDOW +/- 4 DAYS), OPEN-LABEL WEEK 8 ................................ ............................ 38 
10.6 UNSCHEDULED * OR EARLY DISCONTINUATION OF STUDY DRUG OR STUDY PARTICIPATION VISIT.......... 38 
11 ADVERSE EXPERIENCE R EPORTING AND DOCUME N TATION ...............................................................................39  
11.1 ADVERSE EVENTS ................................ ................................ ................................ ................................ ............ 39 
11.2 SERIOUS ADVERSE EXPERIENCE S (SA E)  ................................ ................................ ................................ .......40 
11.3 MEDICAL MONITORING ................................ ................................ ................................ ................................ ...41 
12 DISCONTINUATION AND  REPLACEMENT OF SUBJE CTS........................................................................................41  
12.1 EARLY PERMANENT DISCONTINUATION OF STUDY TR EAT M ENT  ................................ ................................ .41 
12.2 EARLY WITHDRAWAL OF SUBJECTS FROM THE STUDY ................................ ................................ ................. 41 
12.3 REPLACEMENT OF SUBJECTS ................................ ................................ ................................ ........................... 42 
13 PROTOCOL VIOLATIONS  ..........................................................................................................................................42  
14 DATA SAFETY MONITORI NG ...................................................................................................................................42  
15 STATISTICAL METHODS AND CONSIDERATIONS ...................................................................................................42  
15.1 DATA SET S ANALYZED  ................................ ................................ ................................ ................................ ...43 
15.2 DEMOGRAPHIC AND BASEL INE CHARACTERISTICS  ................................ ................................ ....................... 43 
15.3 ANALYSIS OF PRIMARY  ENDPOINT  ................................ ................................ ................................ ................. 43 
15.4 ANALYSIS OF SECONDARY ENDPOINTS  ................................ ................................ ................................ .......... 43 
15.5 INTERIM ANALYSIS ................................ ................................ ................................ ................................ .......... 44 
15.6 SAMPLE SIZE................................ ................................ ................................ ................................ .................... 45 
16 DATA COLLECTION, RET E NTION AND CLI NICAL MO N I TO RIN G  ...........................................................................46  
16.1  DATA COLLECTION INSTRUMENTS ................................ ................................ ................................ ........................... 46 
16.2  DATA MANAGEMENT PROCEDURES ................................ ................................ ................................ ........................ 47 
16.3  DATA QUALI TY CONTROL AND REPORTING  ................................ ................................ ................................ .............. 47 
16.4  SECURITY AND ARCHIVAL OF DATA ................................ ................................ ................................ ......................... 47 
16.5  AVAILABILITY AND RETENTIO N OF INVESTIGATIONAL RECORDS  ................................ ................................ ................... 48 
16.6  MONITORING  ................................ ................................ ................................ ................................ ...................... 48 
16.7  SUBJECT CONFIDENTIALITY  ................................ ................................ ................................ ................................ ....48 
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONS IDERATIONS ............................................................................48  
17.1  PROTOCOL AMENDMENTS ................................ ................................ ................................ ................................ .....49 
17.2  INSTITUTIONAL REVI E W BOARDS  ................................ ................................ ................................ ............................ 49 
17.3  INFORMED CONSENT FORM................................ ................................ ................................ ................................ ...49 
17.4  CONSENT FOR COLLECTION AND USE OF CFF  REGISTRY ID NUMBER ................................ ................................ ........... 50 
17.5  PUBLICATIONS  ................................ ................................ ................................ ................................ ..................... 50 
17.6  INV ES TI GATO R RESP ONSIBILIT IES  ................................ ................................ ................................ ............................ 50 
18 REFERENCES  ..............................................................................................................................................................52  
19 APPENDIX 1 SCHEDULE OF EV EN TS  ........................................................................................................................54  
20 APPENDIX 2 PROTOCOL DEFINED PULMONARY EX ACERBATION DEFINITIO N..................................................56  
 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 5 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 LI ST OF  ABBREVIATIONS  AND ACRONYMS  
AE adverse event  
BAL  bronchoalveolar lavage  
CFR  Code of Federal Regulations  
CF cystic fibrosis  
CFF Cystic Fibrosis Foundation  
CFFT  Cystic Fibrosis Foundation Therapeutics  
CFRSD  Cystic Fibrosis Respiratory Symptom Di ary 
CFRSD -CRISS  CFRSD -Chronic Respiratory Infection Symptom Score  
CFQ -R Cystic Fibrosis Questionnaire - Revised  
CFQ -R RSS  CFQ -R Respiratory Symptom Scale  
CFTR  cystic fibrosis transmembrane conductance regulator  
CRF  case report form  
DSMB  Data Safety Monitoring Board  
ECG  electrocardiogram  
EDC  Electronic data capture  
FDA  Food and Drug Administration  
FEF 25%- 75% forced expiratory flow  
FEV 1 forced expiratory volume over one second  
FVC  forced vital capacity  
GCP  Good Clinical Practice  
HIPAA Health In surance Portability and Accountability Act of 1996  
IRB Institutional Review Board  
IV intravenous  
LFT  Liver function test  
mEq  milliequivale nt  
Pa Pseudomonas aeruginosa  
PFT pulmonary function test  
SAE  serious adverse experience  
TDNCC Therapeutics Dev elopment Network Coordinating Center  
TISP  Tobramycin inhalation solution or powder  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 6 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 PROTOCOL SYNOPSIS  
 
TITLE TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to 
Inhaled Tobramycin. A randomized, placebo-controlled, double -
blinded trial of az ithromycin 500mg thrice weekly in combination 
with inhaled tobramycin  
SPONSOR -
INVESTIGATOR Dave Nichols, MD  (Seattle Children’s Hospital ) 
 
FUNDING 
ORGANIZATION National Institutes of Health/National Heart, Lung, and Blood Institute  
Cystic Fibrosis Founda tion Therapeutics, Inc. (CFFT)  
NUMBER OF SITES  Approximately 40 
RATIONALE  Patients with cystic fibrosis (CF) commonly acquire a chronic airway infection with Pseudomonas aeruginosa  (Pa).  Both inhaled 
tobramycin and oral azithromycin have been proven beneficial in 
these patients and are currently used by the majority of eligible 
patients.  75% of US patients prescribed inhaled tobramycin are also 
prescribed chronic oral azithromycin. We believe that azithromycin 
may be  inhibiting the anti -Pa effects and clinical benefits of inhaled 
tobramycin in clinically infected patients .  This study is designed to 
compare monotherapy with inhaled tobramycin versus  combination 
therapy adding chronic oral azithromycin to inhaled tobramycin.  
STUDY DESIGN This is a prospe ctive, randomized, placebo -controlled , double -blinded  
study of azithromycin in subjects with chronic Pa airway infection 
using inhaled tobramycin.  Subjects who have received two ( 2) or 
more cycles of inhaled tobramycin within the 24 weeks prior to 
enrollm ent will be recruited into the study.   This study will 
investigate whether azithromycin is associated with poorer clinical and microbiologic outcomes as compared to placebo during 
concurrent administration of inhaled tobramycin.   
Eligible s ubjects will b e enrolled and randomized to either 
azithromycin or placebo at Visit 1 , approximately 14 days prior to the 
start day of  their next planned 28-day nebulized solution or dry 
powder tobramycin (TISP) cycle.   Both tobramycin inhalation 
solution (TIS) and tobr amycin inhalation powder (TIP) will be 
allowed, based on clinical prescription.  Tobramycin solution should 
be nebulized with a n approved nebulizer and air compressor . 
Subjects will be randomized in a 1:1 fashion to azithromycin (500 mg 
three times per week ) or matched placebo.  Randomization will be 
stratified by FEV 1 % predicted (25% -50%, >50% -75%, >75%), 
chronic oral azithromycin use for the past 30 days , inhaled tobramycin 
formulation (TIS, TIP), and site . Between Visit 1 (Day -14) and Visit 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 7 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 2 (Day 0), a two -week run -in period will be used to begin 
administration of either azithromycin or placebo.  Among those 
randomized to azithromycin, the 2-week run-in period will be used to 
initiate azithromycin and standardize uptake prior to the start of the 
next T ISP cycle.  Among those randomized to placebo, the run-in 
period will be used as a standardized washout prior to the start of the next TISP cycle.  Subjects will begin TISP at Visit 2 in addition to 
their continued dosing of randomized study drug treatment  
(azithromycin or placebo). Subjects will continue both TISP and study 
drug dosing for 28 days (up until Visit 3 ), which corresponds with the 
end of a clinically prescribed 4 -week cycle of TISP.   
Subjects completing the study through Visit 3 will be offer ed 
participation and consent to an 8-week open-label extension period 
during which azithromycin will be provided.  During the open-label period, subjects will be instructed to remain off of TISP for the first  4-
week period, followed by a 4-week period of T ISP. 
DURATION OF 
SUBJECT PARTICIPATION 
AND DURATION OF 
STUDY  Subjects will be enrolled in the randomized study for up to 42 days (6 
weeks ). 
• Treatment  V1-V2: azithromycin or placebo without TISP:  14 days 
(-2 days/+4 days)  followed by:  
• Treatment  V2-V3: azithromycin or placebo with TISP : 28 days ( -2 
days/+4 days)  
Subjects  participating in the optional open-label extension will be on 
study for up to 98 days (14 weeks ). 
• Treatment V3 -V4: azithromycin without  TISP:  28 days ( -/+4 
days)  followed by:  
• Treatment V4 -V5: azithromycin with TISP  28 days ( -/+4 days)  
The total duration of the study is expected to be approximately 33.5 
months: 30 months for subject recruitment and 3.5 months for the 
final subject enrolled to complete the study.  
PRIMARY OBJECTIVE Determine if  azithromycin impairs the previously -recognized clinical 
benefits of inhaled tobramycin by comparing changes in pulmonary 
function as measured by FEV 1 between subjects randomized to 
azithromycin versus placebo .    
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 8 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 SECONDARY 
OBJECTIVES  The secondary object ives for the randomized period are to:  
• Compare changes in patient -reported quality of life between 
subjects randomized to azithromycin versus placebo  
The secondary exploratory objectives for the randomized period are 
to: 
• Compare the safety profile between  subjects randomized to 
azithromycin versus placebo  
• Compare changes in additional spirometry measures, bacterial 
density, and weight between subjects randomized to azithromycin 
versus placebo  
• Compare rates of pulmonary exacerbations, hospitalizations, and acute antibiotic usage between subjects randomized to 
azithromycin versus placebo  
 
The objectives for those continuing in the open-label extension:  
• Among those randomized to azithromycin and remaining on 
azithromycin, obtain additional data to determine  the long term 
effect of azithromycin on clinical outcomes   
• Among those randomized to placebo and switching to 
azithromycin, compare differences in clinical outcomes observed 
during the randomized and open -label period s 
NUMBER OF SUBJECTS  Approximately 120 subjects  randomized  
SUBJECT SELECTION 
CRITERIA:  
Inclusion Criteria  Inclusion Criteria  for Randomized Period:  
1. Male or female ≥ 12 years of age at Visit 1  
2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or 
more of the following criteria:  
o Sweat chloride equal to or greater than 60 mEq/L by 
quanti tative pilocarpine iontophoresis test (QPIT)  
o Two mutations in the CFTR gene believed to be disease 
causing in the opinion of the site investigator  
o Abnormal nasal potential difference (change in NPD in 
response to a low chloride solution and isoproter enol of less 
polarizing than -7 mV) 
3. Written informed consent (and assent when applicable) obtained 
from subject or subject’s legal representative  
4. Two or more respiratory cultures (sputum, OP swab, BAL sample) 
growing Pa collected within the 12 months  prior to 
randomization,  at least 1 month apart , with at least one collected 
in the 6 months  prior to randomization.   
5. FEV
1% predicted between 25-100% at Visit 1  
 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 9 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 6. Off TISP  and other inhaled anti -pseudomonal antibiotics for at 
least two weeks at  randomization 
7. Willingne ss to begin the next course of TISP at the scheduled 
Visit 2  
8. Use of at least 2 cycles of TISP  within 24 weeks prior to Visit 1 
9. Ability to swallow capsules  (similar in size to pancreatic enzyme 
capsules)  
10. Most recent LFTs less than 4x ULN.  Must be obtained within 12 
months  prior to Visit 1   
11. Current  azithromycin use at Visit 1 or prior chronic azithromycin 
use defined as four  or more consecutive weeks. Subjects do not 
have to be using chronic oral azithromycin at Visit 1 
12. Stable clinical status with no signi ficant change in medication or 
airway clearance routine for four weeks prior to Visit 1, as 
determined by site investigator  
 
Inclusion Criteria  for Open-Label Period : 
1. Completion of the randomized, placebo-controlled period (up 
through Visit 3)  
2. Written info rmed consent (and assent when applicable) obtained 
from subject or subject’s legal representative  
3. Ability for subject to comply with the requirements of the study 
4. Willingness to begin the next course of TISP  at the scheduled 
Visit 4 
5. Clinically stable at Visit 3  as assessed by the site investigator  
SUBJECT 
SELECTION 
CRITERIA:  
Exclusion Criteria  Exclusion Criteria  for Randomized Period:  
1. Weight < 40 kg at Visit 1  
2. For women  of child -bearing potential:  
a. positive pregnancy test at Visit 1 or  
b. lactating or  
c. unwil ling to practice a medically acceptable form of 
contraception (acceptable forms of contraception: 
abstinence, hormonal birth control, intrauterine device, or 
barrier method plus a spermicidal agent), unless surgically 
sterilized or postmenopausal during the study  
3. Inability to perform reproducible spirometry 
4. Inability or unwillingness to cycle off TISP  for one 4-week period 
5. Respiratory culture with Burkholderia cepacia complex species 
within the 24 months prior to Visit 1 
6. Respiratory culture with nontuberculous mycobacteria (NTM) 
within 18 months prior to Visit 1 
7. Use of IV or oral anti-pseudomonal antibiotics within four weeks 
prior to Visit 1  (other than azithromycin)  
 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 10 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 8. Use of an investigational therapy within four weeks prior to     
Visit 1   
9. History of unres olved, abnormal neutropenia  (ANC ≤ 1000 
cells/mm3) 
10. Current u se of systemic corticosteroids equivalent to a daily dose 
more than 10 mg prednisone at Visit 1 
11. Current u se of nelfinavir , warfarin , haloperidol, or methadone  at 
Visit 1   
12. Initiation of approved CFTR modulators less than 30 days prior to 
Visit 1  
13. ECG abnormalities identified at Visit 1 that require prompt, 
further medical evaluation or QTc interval > 480 msec for males 
and >486 msec for females at Visit 1  
14. Any other condition that, in the opinion of the site  
investigator/designe e, would preclude informed consent or assent, 
make study participation unsafe, complicate interpretation of 
study outcome data, or otherwise interfere with achieving the 
study objectives  
 
Exclusion Criteria  for Open-Label Period : 
1. Weight < 40 kg at Visit 3 
2. For women of child bearing potential: unwilling to practice a 
medically acceptable form of contraception (acceptable forms of 
contraception: abstinence, hormonal birth control, intrauterine device, or barrier method plus a spermicidal agent), unless 
surgic ally sterilized or postmenopausal during the study  
3. Identified r espiratory culture positive for NTM  or Burkholderia 
cepacia  complex species during randomized study period 
4. Use of an investigational therapy at Visit 3 
5. Current use of systemic corticosteroids equivalent to a daily dose 
more than 10 mg prednisone  
6. Current use of nelfinavir , warfarin , haloperidol, or methadone   
7. Any other condition that, in the opinion of the site 
investigator/designee, would preclude informed consent or assent, 
make study partici pation unsafe, complicate interpretation of 
study outcome data, or otherwise interfere with achieving the 
study objectives  
TEST PRODUCT, 
DOSE, AND ROUTE OF 
ADMINISTRATION Over -encapsulated azithromycin tablets will be provided during the 
randomized period of the study.  Azithromycin will be dosed as one 
500 mg capsule  three times per week .  
During the open-label extension period, azithromycin 500 mg tablets 
(without over -encapsulation) will be provided by the site pharmacy 
and dosed three times per week.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 11 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 CONTROL 
PRODUCT, DOSE 
AND ROUTE OF 
ADMINISTRATION Placebo , matching the appearance of the azithromycin capsules  and 
comp rised of the same capsule material as the test product will be 
provided during the  randomized period of the  study. Placebo will be 
dosed as one capsule  three times per week . 
STANDARD OF CARE 
TREATMENT: TISP  In this study, TISP is given as standard of care , will be based on 
clinical prescription for 28 days on,  followed by 28 days off , and will 
conform to manufacturer administration guidel ines.   
CONCOMMITANT MEDICATIONS  Allowed:  For both the randomized and open-label periods,  standard 
therapy for CF is allowed except for treatments noted in the 
conditionally allowed and prohibited medications section s below.  
Ongoing chronic treatment (>30 days prior to Visit 1) with inhaled 
dornase alpha, hypertonic saline, short and long acting 
bronchodilators, FDA -approved CFTR modulators, high dose 
ibuprofen, low -dose inhaled or systemic steroids  and airway clearance 
is allowed.   
Conditionally Allowed : Acute treatment with drugs categorized as 
known to prolong QT interval  is allowed  according to the following:  
• For drugs commonly used to treat CF patients (e.g.  
ciprofloxacin, levofloxacin, moxifloxacin, fluconazole, propofol, 
sevoflurane, ondansetron),  study drug (azithromycin or placebo) 
or open-label azithromycin does not  need to be stopped.   
• For all other drugs categorized as known to prolong QT interval , 
acute use is allowed but study drug (azithromycin or placebo) or 
open-label azithromycin must be temporarily stopped during use 
of these medications .  After acute treatment is completed, 
subjects  should re start study drug or open-label azithromycin on 
the next scheduled treatment day.  
• Chronic  treatment (>30 days prior to Visit 1) with antidepressant 
medications citalopram and escitalopram is allowed without affecting study participation  if:  
o The subject has been using both chronic oral azithromycin 
AND citalopram (or escitalopram) consistently for greater 
than 30 days at Visit 1   
AND 
o The Visit 1  ECG  demonstrates QTc  within the normal limits 
as defined by the protocol  
Drugs known to prolong QT interval are described as follows: 
“Substantial evidence supports the conclusion that these drugs prolong 
the QT interval AND are clearly associated with a risk  of torsades de 
pointes (TdP), even when taken as directed in official labeling” , and 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 12 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 are listed on the CredibleMeds® Websit e (Composite List of All QT 
Drugs  under the category “Known Risk of TdP” ).  
Acute use of macrolide antibiotics may be required for certain 
infections and is allowed but also requires temporarily stopping the 
study drug or open-label azithromycin . The study drug or open-label 
azithromycin should be resta rted on the next scheduled day following 
completion of the prescribed macrolide antibiotic.  
Treatment for pulmonary exacerbations as required for acute care is 
allowed except for treatments noted in the prohibited medications 
section below.  Physicians are  encouraged to prescribe acute antibiotic 
therapy and initiate or increase the dose of acute systemic 
corticosteroids (defined as less than 10 days) only in the presence of 
increased symptoms  suggesting a pulmonary exacerbation.  
 
Prohibited:  For both the randomized and open-l abel periods, t he 
following medications are prohibited (for the randomized period, 
between Visit 1 through Visit 3; for the open-label period, between 
Visit 3 and Visit 5) .   
o Investigational therapies  
o Chronic inhaled antibiotics other than cycled TISP (e.g., 
Cayston®, colistin). Chronic treatment is defined as inhaled 
antibiotics prescribed as a maintenance therapy and not used temporarily to treat a pulmonary exacerbation.  
o Increase in chronic systemic corticosteroid dose beyond 
predni sone equivalent of 10 mg per day,  or initiation of 
chronic systemic  (oral or intravenous) corticosteroids  at any 
dose. Chronic use is defined as greater than 10 days 
continuous use.   
o New or increase in ibuprofen dose of greater than 800 mg total 
dose per 24 hours for more than 5 days  
o Nelfinavir, warfarin, haloperidol, or methadone  
PRIMARY ENPOINT  Difference between the azithromycin and placebo treatment groups in 
the relative change in FEV 1(liters) from randomization (Visit 1) to 
Visit 3 . 
SECONDARY 
ENDPO INTS  Randomized Period  
Secondary Endpoints : 
• Difference between the azithromycin and placebo treatment groups in the relative change in FEV
1(liters) during administration 
of TISP from Visit 2 to Visit 3 . 
• Difference between the azithromycin and placebo treat ment 
groups in the change  from Visit 1  to Visit 3 in the Cystic Fibrosis 
Respiratory Symptom Diary (CFRSD) - Chronic Respiratory 
Infection Symptom Score (CRISS©)  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 13 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 • Difference between the azithromycin and placebo treatment 
groups in the change from Visit 1  to Visit 3 in the scales derived 
from the CFQ -R  
 
Exploratory Secondary Endpoints : 
• Difference in adverse event rates  and rates of abnormal QTc 
parameters from Visit 1  through Visit 3 between the azithromycin 
and placebo treatment groups  
• Difference in the p roportion of subjects hospitalized from Visit 1  
through Visit 3 between the azithromycin and placebo treatment 
groups Difference in the proportion of subjects prescribed acute 
oral, inhaled and IV antibiotics from Visit 1 through Visit 3 
between the azithr omycin and placebo treatment groups  
• Difference in the proportion of subjects experiencing a protocol -
defined pulmonary exacerbation requiring antibiotic therapy from 
Visit 1  through Visit 3 between the azithromycin and placebo 
treatment groups  
• Difference  between the azithromycin and placebo treatment 
groups in the absolute change from Visit 1  to Visit 3 and Visit 2 to 
3 in FEV 1 (liters and % predicted), absolute and relative change in 
FVC (liters and % predicted), and absolute and relative change in 
FEF 25-75%  
• Difference between the azithromycin and placebo treatment 
groups in the change from Visit 1 to Visit 3 in weight  
• Difference in the change from Visit 1  to Visit 3 in sputum Pa  
bacterial density between the azithromycin and placebo treatment 
groups  
Open-Label Period  
• Among those randomized to azithromycin and remaining on 
azithromycin, longitudinal changes and/or rates in all clinical 
outcomes across   the randomized and open-label periods  
• Among those randomized to placebo and switching to 
azithromycin,  differences in all clinical outcomes between the 
randomized and open -label periods  
PLANNED INTERIM ANALYSES  An independent data monitoring board (DSMB) will review 
comprehensive interim report s when approximately 50% and 75% of 
patients have completed the randomized period of the study. Regular 
reporting frequency to the DSMB is detailed in the DSMB charter.  A 
priori  interim stopping rules for futility and efficacy/harm with 
respect to the primary endpoint are outlined in the DSMB charter. 
Serious advers e experiences  (SAEs) will be monitored by the 
committee on an ongoing basis throughout the study.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 14 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 STATISTICS  
Primary Analysis Plan  All analyses will be performed using a  modified  intent -to-treat ( m-
ITT) population, which is defined as all randomized subje cts who 
received  at least one dose of study drug.  All tests will be two -sided 
and evaluated at a 0.05 level of significance.  
 
The primary endpoint will be the difference between the azithromycin 
and placebo treatment groups in the relative change from Visit 1 to 
Visit 3 in FEV 1 (liters).  The primary endpoint will be compared 
between treatment groups using linear regression adjusted for 
randomization strata . Least squares means and the treatment effect for 
the relative  change will be presented as well as corresponding 95% 
confidence interval and p-values. The p-values will be evaluated 
against a two -sided 0.05 level of significance.  
Rationale for Number 
of Subjects  The primary endpoint is the difference bet ween the azithromycin and 
placebo treatment groups in the relative change from Visit 1  to Visit 3 
in FEV 1 (liters).  Data from prior published studies of similar duration 
are available to estimate sample size and power for the study 
including a randomized,  placebo -controlled trial of azithromycin in 
individuals with CF chronically infected with Pa and a randomized, 
placebo controlled trial of aztreonam lysine similarly among those 
with chronic Pa.  These studies suggest a standard deviation of the 
relative change in FEV 1 ranging from 10 to  16.  Based on these prior 
studies, we anticipate the relative change in FEV 1 from Visit 1 to Visit 
3 to be -2% in the azithromycin arm and +6.85%  in the placebo arm 
for an overall treatment effect of 8.65%.    A sample size of 110 
provides 85% power to detect a treatment effect of 7.5% or greater 
assuming a standard deviation of 13.  110 subjects provide s 93% 
power to dete ct a treatment effect similar to what was observed in the 
preliminary data (8.65%)  assuming a standard deviation of 13.   It is 
noteworthy that the standard deviation from more recently completed 
studies CF studies have observed standard deviations in short  term 
relative change in FEV (liters) ranging from 8-11, confirming our 
conservatism in the standard deviation estimate used for our sample 
size calculations.   Assuming a standard deviation of 11, a sample size 
of 110 provides 85% power to detect a treatm ent effect of 6.3% or 
greater in favor of the placebo group.    
It is anticipated from prior CF trials conducted through the TDNCC 
that the attrition rate will be less than 10%, and thus a sample size of 
120 will ensure at least 110 subjects will complete t he trial.   
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 15 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
  
1 BACKGROUND 
Projected median survival of those with cystic fibrosis (CF) has dramatically improved in recent 
decades, largely as a result of new medications and therapies.  Pseudomonas aeruginosa (Pa) is 
the most common pathogen in the airways of people with CF. By early adolescence, half of all 
patients with CF are chronically infected with Pa1.  This prevalence increases to 70% or more  by 
early adulthood, and persistent P a airway inf ection is linked to more rapid loss of lung function 
and earlier mortality2,3.  Inhaled antibiotics achieve high airway concentrations while avoiding 
many safety concerns associated with prolonged systemic drug exposure4,5. Strategies to 
eradicate initial Pa airway infection or treat chronic infection have proven beneficial6-9.  
The aminoglycoside tobramycin was the first inhaled ant i-pseudomonal antibiotic commercially 
developed for CF and remains the most prescribed inhaled antibiotic used in the US1.  Roughly 
two thirds of all US patients with CF and chronic Pa are prescrib ed inhaled tobramycin—
typically as 28 days of on-off cycles. Long-term use of oral azithromycin has also been shown to 
improve lung function and reduce exacerbations in CF patients with chronic Pa airway 
infection10,11.  While the mechanism of action is uncertain and potentially multifactorial, 
azithromycin has immunomodulatory effects and may function as an anti -inflammatory agent in 
CF12-15. Azithromycin is widely prescribed and is now the most common chronic antibiotic used 
in CF patients with persistent Pa1.  In queries of recent clinical trials and the US CF Foundation 
National Patient Registry, we find that ~70% of all patients with P a and 75% of those prescribed 
inhaled tobramycin are now also prescribed oral  azithromycin on a chronic basis.  
Potential interactions between concomitant medications and mechanisms for antibiotic resistance 
in CF are poorly understood.  These issues have been cited in current CF consensus treatment 
guidelines as two key unanswered questions in need of further study16. Based on recent pre -
clinical research demonstrating antagonism between azithromycin and tobramycin, but not the 
fluoroquin olone, ciprofloxacin17, we  hypothesized that azithromycin may selectively inhibit 
tobramycin when targeting Pa airway infection in CF lung disease.  We have now observed a 
selective, antagonistic drug interaction between azithromycin and tobramycin in two in vitro 
models of biofilm  growth with Pa, two animal models of biofilm -based Pa infection, and two 
non-overlapping CF clinical trials when retrospectively analyzing the impact of concomitant 
azithromycin use on clinical and microbiological outcome measures.  
In-vitro  Data 
Initial s tudies were conducted with the laboratory strain of Pa PA0118. Using a flow cell biofilm 
culture method, we observe significant antibiotic effects, manifested as reduced biofilm biomass, 
with antibiot ics individually (Fig ure 1a). However, when azithromycin was added, we observed 
neutral to increased effect with ciprofloxacin (Fig ure 1b) but antagonist ic effects with 
tobramycin (Figure  1c).  
 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 16 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
  
Figure 1a            Figure 1b    Figure 1c  
 
 
 
 
 
 
 
 
 
 
 *P<0.01   ∞P<0.001 
 
Additional studies in the flow -cell biofilm model were conducted using 15 CF clinical isolates of 
Pa
19. Twelve of the isolates grew sufficient biofilms to be tested in the antibiotic comparison 
studies. Of those 12,  six showed antagonism when azithr omycin was added to tobramycin. We 
then tested aztreonam in those six isolates and observed neutral effects in three isolates  and 
additive effects in three  isolates (Fig ure 2). The flow -cell system is devoid of any mammalian 
tissue. These data suggest that  the suspected drug interaction occurs directly between the 
antibiotics in the context of bacterial infection rather than indirectly through altered host 
response.  
Figure 2 
 
 

Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 17 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 More recently, we have developed a biofilm aggregate model that incorporates lys ed human 
neutrophils to enhance biofilm growth20. In this model, Pa develops non-surface attached 
biofilms suspended in nutrient poor media containing the lysed neutrophils, and may more 
closely resemble the bacterial communities that have been documented in airway secretions from 
people with CF. We have tested 30 CF clinical isolates in this model. Ten isolates were collected from a clinical trial, 10 were collect ed from patients at National Jewish Health, and 10 were 
obtained from the CF repository at Seattle, WA.  
In the biofilm aggregate model, we observe highly significant reduction in bacterial killing when 
azithromycin is added to tobramycin, with 2-3 log anta gonism (100-1000 fold; Fig ure 3a). To 
date, we do not observe antagonism with other antibiotics commonly used for inhalation therapy 
in CF (Fig ure 3b; effect of azithromycin when added to anti -Pa antibiotics ). 
 
      Figure 3a       Figure 3b 
 
 
 
  
  
  
 
  
In-vivo  Animal M odel Data 
As part of a research project sponsored by the U .S. Department of Defense, we tested the ability 
of early azithromycin treatment, with or without subsequent additional antibiotics, to reduce Pa 
infection in cutaneous thermal injur y (i.e. , burn wound)17.   Pa grows as a biofilm in the presence 
of exuberant neutrophilic inflammation in both burn wound infections and CF lung disease21-23. 
Tobramycin alone effective ly reduced Pa infection at the wound site and systemic spread to the 
lung (Figure  4a). As predicted, azithromycin had additive antibacterial effects when combined 
with subsequent ciprofloxacin treatment.  However, counter to our hypothesis, we found that t he 
burden of P a infection both at the wound site and systemically (lung) greatly increased when 
azithromycin treatment was followed by tobramycin (Figure  4b). Infection with combined 
azithromycin and tobramycin was no better than normal saline -treated cont rol. 

Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 18 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
  
Figure 4a   
       Wound Site       Lung                       
 
  
 
     Figure 4b      Wound Site       Lung 
        
 
We then conducted follow up studies using a fibrin-based plug model to retain a CF clinical 
strain of Pa within the airways of mic e overexpressing the epithelial sodium channel (ENaC). 
The transgenic ENaC mice, despite normal CFTR,  model airway dehydration and chronic 
neutrophilic bronchitis present in human CF patients. In this experiment, animals were treated 
with azithromycin and/ or tobramycin together and at the same time for 48 hours prior to tissue 
specimen collection  (Figure 4c) . We observed that azithromycin reduced the ability of systemic 
tobramycin to kill Pa in the lung of these animals (unpublished).  
Figure 4c 
 
  
 
 
  

Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 19 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 Clinical Trials Data  
We have analyzed the concomitant use of azithromycin in two CF clinical trials testing inhaled 
antibiotic therapy in CF subjects with chronic Pa airway infection. One is the active comparator 
study of inhaled tobramycin and inhaled aztreonam published in 20127.  The other is the AIR -
CF2 study comparing twice daily vs. three times daily inhaled aztreonam lysine, following a 4-
week run-in period with inhaled tobramycin24. In both studies, we observe that subjects reporting 
concomitant use of chronic oral azithromycin have little improvement in clinical outcome 
measures while receiving inhaled tobramycin. Subjects without azithromycin us e appear to 
respond similarly to inhaled tobramycin or inhaled aztreonam lysine. Azithromycin use does not 
appear to significantly alter the response to inhaled aztreonam lysine in these trials. This pattern 
of selective drug interaction between azithromyc in and an inhaled aminoglycoside is consistent 
across multiple related outcome measures. In these studies, the mean age of subjects is 
approximately 25 years, mean FEV 1 is approximately 55% predicted, and over 70% of enrolled 
subjects reported azithromycin as a concomitant medication.  
Active Comparator Trial  
Subjects randomized to inhaled tobramycin show a significant different change in FEV 1% over 
one cycle (Fig ure 5a) and three  cycles (Fig ure 5b) of inhaled antibiotics based on azithromycin 
use.  Change  in FEV 1% in subjects randomized to inhaled aztreonam lysine was not significantly 
affected by azithromycin use. Users of azithromycin failed to reach a clinically significant change in self -reported quality of life over four  weeks of inhaled tobramycin ba sed on the CFQ -
R respiratory symptom scale (Figure 5c) and experienced greater need for additional intravenous 
or inhaled antibiotic therapy (Figure  5d). Full analyses of azithromycin use in this study have 
been published
19. 
 
             
  
     
Figure 5a  
 Figure 5b 
Figure 5c  
 Figure 5d 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 20 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 AIR-CF2 Clinical Tr ial 
During the 4-week run-in period with inhaled tobramycin, subjects with concomitant 
azithromycin use had lesser improvement in FEV 1 (Figures 6a and 6b). Immediately after 
inhaled tobramycin use, subjects received inhaled aztreonam lysine. Users of azit hromycin had 
significantly greater improvement in FEV 1 with the non-aminoglycoside, aztreonam, than during 
the run-in period with tobramycin. Subjects without azithromycin use had approximately 4% 
relative increase in FEV 1 (liters) during both the tobramyc in and subsequent aztreonam lysine 
periods of this study. Self -reported quality of life, again based on the change in CFQR -RSS, was 
also similarly impacted by azithromycin use (Figure  6c).   
Figure 6a         Figure 6b     
 
 
 
 
 
 
 
 
2 STUDY RATIONALE  
If our hypotheses are appropriately tested and proven correct, then current practice 
recommendations for tens of thousands of patients with CF worldwide may be altered.  Based on 
the CF registry data, we estimate there are >10,000 patients in the US currently pre scribed 
azithromycin and inhaled tobramycin.  Over a lifetime, over 50% of patients will meet the 
clinical criteria to be prescribed these two medications as chronic therapy.  Additional concerns 
extend to the use of intravenous (IV) tobramycin, which is s elected twice as often as any other 
anti-pseudomonal drug for CF pulmonary exacerbations25. Impact of azithromycin on IV 
aminoglycosides is beyond the scope of this proj ect but demonstrate broader implications for our 
research.  There are sizable financial impacts related to the cost of these medications and outcomes related to decline in lung function (e.g. , pulmonary exacerbations, quality of life, and 
survival).  
Taken  together, the data summarized above provide strong evidence that a drug-drug interaction 
may be present in current CF care recommendations.  However, there is obvious risk for confounding by indication with azithromycin use when analyzing clinical data re trospectively.  
Reported baseline characteristics are similar between users and non -users of azithromycin in 
these data, but multiple recognized and unrecognized variables that may contribute to pulmonary 
decline are not accounted for.  Therefore, a prospe ctive study to both control for such 
confounders and intentionally monitor drug use is needed.  
Our primary and secondary outcomes focus on relative change in FEV
1 (liters ) and self -reported, 
disease related quality of life. Additional information, such as comparison with alternative 
inhaled antibiotics or the effect on pulmonary exacerbations, is viewed as important but would 
Figure 6c  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 21 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 require a much larger study. The planned design will allow us to test the primary hypothesis of 
an adverse drug interaction between a zithromycin and inhaled tobramycin. It may be that both 
agents, when used without the other, are beneficial but that the combination is disadvantageous. 
If our theory is proven through this study,  then these data can be used to justify and design 
additiona l research to address other important and related questions.  
2.1 Risk / Benefit Assessment  
No experimental or new medications are being introduced to subjects during this study.  
Removal of chronic azithromycin may decrease lung function or increase the rate of pulmonary 
exacerbation, based on prior studies of azithromycin in similar patients10,26.  Our preliminar y 
data does  not support this concern and suggest that removing azithromycin may be protective in 
the majority of subjects also using inhaled tobramycin.  This includes better clinical outcomes in 
lung function (FEV 1), patient reported quality of life, and time to need additional antibiotics19.  
However, a withdrawal study of either medication has never been reported and our preliminary 
data on lung function may not fully predict the risk of pulmonary exacerbation.  Subjects 
experiencing a pulmonary exacerbation will be treated  but will not  be removed from the study.  
Identifying an undesirable drug-drug interaction pertinent to over 50% of US patients with CF 
has clear and important safety and efficacy implications.  Given that both of these medications 
benefit from str ong support in US consensus guidelines, answering this question is a high 
priority.  
Recent reports raise concern about potential proarrhythmic cardiotoxicity with oral azithromycin 
treatment in non-CF populations27.  Patients with CF account for a significant portion of chronic 
azithromycin use in the US and cardiac arrhythmias have not been linked to this therapy.  
Similarly, the relative risk of cardiovascular death  attributable to azithromycin was reported as 
<1 per 100,000 antibiotic courses in low risk patients27.  There are approximately 30,000 CF 
patients in the entire US,  and a repeat study found no increased risk in younger, lower risk adult 
populations28. However, this study provides an opportunity to analyze electrocardiogram s 
(ECGs ), focusing on any effect on QT c interval, in a group of CF subjects both on and off of 
azithromycin.   
3 STUDY OBJECTIVES  
3.1 Primary Objective  
The primary objective of this study is to determine if azithromycin impairs the previously-
recognized clinical benefits of inhaled tobramycin by comparing changes in pulmonary function 
as measured by FEV 1 between subjects randomized to azithromycin versus placebo.  
3.2 Secondary Objectives  
The secondary objectives for the randomized period are to:  
o Compare changes in patient -reported quality of life between subjec ts randomized to 
azithromycin versus placebo  
The secondary exploratory objectives for the randomized period are to:  
o Compare the safety profile between subjects randomized to azithromycin versus placebo.   
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 22 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 o Compare changes in additional spirometry measures, bacterial density, and weight 
between subjects randomized to azithromycin versus placebo  
o Compare rates of pulmonary exacerbations, hospitalizations, and acute antibiotic usage 
between subjects randomized to azithromycin versus placebo  
The objectives for those continuing in the open-label extension:  
o Among those randomized to azithromycin and remaining on azithromycin, obtain 
additional data to determine the long term effect of azithromycin on clinical outcomes   
o Among those randomized to placebo and switching to azithromycin, compare differences in clinical outcomes observed during the randomized and open-label periods  
4 STUDY DESIGN 
4.1 Study Overview  
This is a prospective, randomized, placebo-controlled , double -blinded study of azithromycin in 
subjects with chr onic Pa airway infection using inhaled tobramycin.  Subjects who have received 
two ( 2) or more cycles of inhaled tobramycin within the 24 weeks prior to enrollment will be 
recruited into the study.  This study will investigate whether azithromycin is assoc iated with 
poorer clinical and microbiologic outcomes as compared to placebo during concurrent 
administration of inhaled tobramycin.   
Approximately 120 eligible subjects will be enrolled and randomized to either azithromycin or 
placebo at Visit 1 , approxi mately 14 days prior to the start day of  their next planned 28-day 
nebulized solution or dry powder tobramycin (TISP) cycle.  Both tobramycin inhalation solution 
(TIS) and tobramycin inhalation powder (TIP) will be allowed, based on clinical prescription.  
Tobramycin solution should be nebulized with a n approved nebulizer and air compressor . 
Subjects will be randomized in a 1:1 fashion to azithromycin (500 mg three times per week ) or 
matched placebo.  Randomization will be stratified by FEV
1 % predicted (25% -50%, >50% -75%, 
>75%) , chronic oral azithromycin use for the past 30 days , inhaled tobramycin formulation (TIS 
or TIP), and site.  Between Visit 1 (Day -14) and Visit 2 (Day 0), a two-week run-in period will 
be used to begin administration of either azithromycin or placebo.   Among those randomized to 
azithromycin, the 2-week run-in period will be used to initiate azithromycin and standardize 
uptake prior to the start of the next TISP  cycle.  Among those randomized to placebo, the run-in 
period will be use d as a standardized washout prior to the start of the next TISP cycle.  Subjects 
will begin TISP at Visit 2 in addition to their continued dosing of randomized study drug 
treatment ( azithromycin or placebo). Subjects will continue both TISP and study drug dosing for 
28 days (up until Visit 3 ), which corresponds with the end of a clinically prescribed 4 -week cycle 
of TISP.   
Subjects completing the study through Visit 3 will be offered participation and consent to an 8-
week open-label extension period during which azithromycin will be provided.  During the open-
label period, subjects will be instructed to remain off of TISP for the first  4-week period, 
followed by a 4-week period of TISP .  
The total duration of the study is expected to be approximately 33.5 m onths: 30 months for 
subject recruitment and 3.5 months for the final subject enrolled to complete the study (Figure 
7). 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 23 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 Figure  7.  Study Schematic  
 
A follow up safety visit is not necessary for this study as it does not expose subjects to new or 
investig ational products.  
5 CRITERIA FOR EVALUAT ION 
5.1 Primary Endpoint  
The primary endpoint in the study is the difference between the azithromycin and placebo 
treatment groups in the relative change in FEV 1 (liters) from randomization (Visit 1)  to Visit 3.   
5.2 Seconda ry Endpoints  
Randomized Period 
Secondary Endpoints : 
• Difference between the azithromycin and placebo treatment groups in the relative change in 
FEV 1(liters) during administration of TISP from Visit 2 to Visit 3.  
• Difference between the azithromycin and placebo treatment groups in the change  from Visit 
1 to Visit 3 in the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) - Chronic 
Respiratory Infection Symptom Score (CRISS©)  
• Difference between the azithromycin and placebo treatment groups in the change from Visit 
1 to Visit 3 in the scales derived from the CFQ -R  
 
Exploratory Secondary Endpoints : 
• Difference in adverse event rates  and rates of abnormal QTc parameters from Visit 1  through 
Visit 3 between the azithromycin and placebo treatment groups  
• Difference in the proportion of subjects hospitalized from Visit 1  through Visit 3 between the 
azithromycin and placebo treatment groups Difference in the proportion of subjects 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 24 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 prescribed acute oral, inhaled and IV antibiotics from Visit 1  through Visit 3 between th e 
azithromycin and placebo treatment groups  
• Difference in the proportion of subjects experiencing a protocol -defined pulmonary 
exacerbation requiring antibiotic therapy from Visit 1  through Visit 3 between the 
azithromycin and placebo treatment groups  
• Difference between the azithromycin and placebo treatment groups in the absolute change 
from Visit 1  to Visit 3 and Visit 2 to Visit 3 in FEV 1 (liters and % predicted), absolute and 
relative change in FVC (liters and % predicted), and absolute and relative c hange in FEF 25-
75%  
• Difference between the azithromycin and placebo treatment groups in the change from Visit 
1 to Visit 3 in weight  
• Difference in the change from Visit 1  to Visit 3 in sputum Pa  bacterial density between  the 
azithromycin and placebo treat ment groups  
 
Open-Label Period  
• Among those randomized to azithromycin and remaining on azithromycin, longitudinal 
changes and/or rates in all clinical outcomes across   the randomized and open-label periods  
• Among those randomized to placebo and switching t o azithromycin, differences in all 
clinical outcomes between the randomized and open-label periods  
6 SUBJECT SELECTION  
6.1 Study Population 
Subjects with a diagnosis of CF who meet all of the inclusion and none of the exclusion criteria 
will be eligible for enrollment in this study.   
6.2 Inclusion Criteria  
Inclusion Criteria for Randomized Period:  
1. Male or female ≥ 12 years of age at Visit 1  
2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent 
with the CF phenotype and one or more of the following criteria:  
o Sweat chloride equal to or greater than 60 mEq/L by quantitative pilocarpine 
iontophoresis test (QPIT)  
o Two mutations in the CFTR gene believed to be disease causing in the opinion of the site 
investigator  
o Abnormal nasal potentia l difference (change in NPD in response to a low chloride 
solution and isoproter enol of less polarizing than -7 mV) 
3. Written informed consent (and assent when applicable) obtained from subject or subject’s legal representative 
4. Two or more respiratory cultur es (sputum, OP swab, BAL sample) growing Pa collected 
within the 12 months prior to randomization , at least 1 month apart, with at least one 
collected in the 6 months prior to randomization  
5. FEV
1% predicted between 25-100% at Visit 1 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 25 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 6. Off TISP and other inhaled anti -pseudomonal antibiotics for at least two weeks at 
randomization 
7. Willingness  to begin the next course of TISP at the scheduled Visit 2  
8. Use of at least 2 cycles of TISP within 24 weeks prior to Visit 1 
9. Ability to swallow capsules  (similar in size  to pancreatic enzyme capsules)  
10. Most recent LFTs less than 4x ULN.  Must be obtained within 12 months prior to Visit 1   
11. Current azithromycin use at Visit 1 or prior chronic azithromycin use defined as four or more 
consecutive weeks. Subjects do not have t o be using chronic oral azithromycin at Visit 1 
12. Stable clinical status with no significant change in medication or airway clearance routine for 
four weeks prior to Visit 1, as determined by site investigator  
Inclusion Criteria for Open-Label Period:  
1. Comple tion of the randomized, placebo-controlled period (up through Visit 3)  
2. Written informed consent (and assent when applicable) obtained from subject or subject’s legal representative  
3. Ability for subject to comply with the requirements of the study 
4. Willingne ss to begin the next course of TISP at the scheduled Visit 4 
5. Clinically stable at Visit 3 as assessed by the site investigator  
6.3 Exclusion Criteria  
Exclusion Criteria  for Randomized Period:  
1. Weight < 40 kg at Visit 1 
2. For women  of child -bearing potential:  
a. positive pregnancy test at Visit 1 or  
b. lactating or  
c. unwilling to practice a medically acceptable form of contraception (acceptable forms of 
contraception: abstinence, hormonal birth control, intrauterine device, or barrier method 
plus a spermicidal agent), unl ess surgically sterilized or postmenopausal during the study  
3. Inability to perform reproducible spirometry 
4. Inability or unwillingness to cycle off TISP for one 4-week period 
5. Respiratory culture with Burkholderia cepacia complex species within the 24 months  prior to 
Visit 1  
6. Respiratory culture with nontuberculous mycobacteria (NTM) within 18 months prior to 
Visit 1  
7. Use of IV or oral anti -pseudomonal antibiotics within four weeks prior to Visit 1 (other than 
azithromycin)  
8. Use of an investigational therapy wit hin four weeks prior to Visit 1  
9. History of unresolved, abnormal neutropenia (ANC ≤ 1000 cells/mm3) 
10. Current use of systemic corticosteroids equivalent to a daily dose more than 10 mg 
prednisone at Visit 1 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 26 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 11. Current use of nelfinavir , warfarin , haloperidol, or methadone  at Visit 1  
12. Initiatio n of approved CFTR modulators less than 30 days prior to Visit 1 
13. ECG abnormalities identified at Visit 1 that require prompt, further medical evaluation or 
QTc interval > 480 msec for males and >486 msec for females at Visit 1  
14. Any other condition that, in t he opinion of the site investigator/designee, would preclude 
informed consent or assent, make study participation unsafe, complicate interpretation of 
study outcome data, or otherwise interfere with achieving the study objectives  
 
Exclusion Criteria  for Op en-Label Period : 
1. Weight < 40 kg at Visit 3 
2. For women of child bearing potential: unwilling to practice a medically acceptable form of 
contraception (acceptable forms of contraception: abstinence, hormonal birth control, 
intrauterine device, or barrier meth od plus a spermicidal agent), unless surgically sterilized or 
postmenopausal during the study  
3. Identified respiratory culture positive for NTM or Burkholderia cepacia  complex species 
during randomized study period 
4. Use of an investigational therapy at Visit  3 
5. Current use of systemic corticosteroids equivalent to a daily dose more than 10 mg 
prednisone  
6. Current use of nelfinavir , warfarin , haloperidol, or methadone   
7. Any other condition that, in the opinion of the site investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of 
study outcome data, or otherwise interfere with achieving the study objectives  
6.4 Study Specific Tolerance for Inclusion/Exclusion Criteria  
Subjects who fail to meet one or  more of the inclusion criteria or who meet any of the exclusion 
criteria will not be enrolled in this study. Waivers of any of the above study entry criteria will not 
be granted.  
6.5 Screen Fail Criteria  
Any consented patient who is excluded from the study be fore randomization is considered a 
screen failure. All screen failures must be documented with the reason for the screen failure 
adequately stated. If a subject screen fails prior to randomization , they can be rescreened once if 
the site staff feels they m eet eligibility criteria and following confirmation from the Sponsor -
Investigator  or designee .  Rescreened subjects are required  to complete all screening procedures 
(i.e., test results from previous screenings cannot be used).    
7 CONCURRENT MEDICATIO NS 
All subjects should be maintained on the same medications throughout the entire study period, as 
medically feasible, with no introduction of new chronic therapies.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 27 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 7.1 Allowed Medications and Treatments  
For both the randomized and open-label periods,  standard therapy for CF is allowed except for 
treatments noted in the conditionally allowed and prohibited medications section s below.  
Ongoing chronic treatment (>30 days prior to Visit 1) with inhaled dornase alpha, hypertonic 
saline, short and long acting bronchodilat ors, FDA -approved CFTR modulators, high dose 
ibuprofen, low -dose inhaled or systemic steroids  and airway clearance is allowed.   
7.2 Conditionally Allowed Medications and Treatments  
Acute treatment with drugs categorized as known to prolong QT interval  is allowed  according to 
the following:  
• For drugs commonly used to treat CF patients (e.g.  ciprofloxacin, levofloxacin, 
moxifloxacin, fluconazole, propofol, sevoflurane, ondansetron), study drug (azithromycin 
or placebo) or open-label azithromycin does not  need to be stopped.   
• For all other drugs categorized as known to prolong QT interval , acute use is allowed but 
study drug (azithromycin or placebo) or open-label azithromycin must be temporarily 
stopped during use of these medications.  After acute treatment is completed, subjects 
should re -start study drug or open-label azithromycin on the next scheduled treatment day.  
• Ongoing chronic treatment (>30 days prior to Visit 1) with antidepressant medications 
citalopram and escitalopram is allowed without  affect ing study participation if: 
o The subject has been using both chronic oral azithromycin AND citalopram (or 
escitalopram) consistently for greater than 30 days at Visit 1   
AND 
o The Visit 1  ECG demonstrates QTc  within the normal limits as defined by the protocol  
Drugs known to prolong QT interval are described as follows: “ Substantial evidence supports the 
conclusion that these drugs prolong the QT interval AND are clearly associated with a risk of torsades de pointes (TdP), even when taken as  directed in offici al labeling”, and listed on the 
CredibleMeds
® Websit e (Composite List of All QT Drugs  under the category “Known Risk of 
TdP” ). 
Acute use of macrolide antibiotics may be req uired for certain infections and is allowed but also 
requires temporarily stopping the study drug or open-label azithromycin . The study drug or 
open-label azithromycin should be restarted on the next scheduled day following completion of 
the prescribed macrolide antibiotic.  
Treatment for pulmonary exacerbations as required for acute care is allowed except for treatments noted in the prohibited medications section below.  Physicians are encouraged to 
prescribe acute antibiotic therapy and initiate or increas e the dose of acute systemic 
corticosteroids (defined as less than 10 days) only in the presence of increased symptoms  
suggesting a pulmonary exacerbation.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 28 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 7.3 Prohibited Medications and Treatments  
For both the randomized and open-l abel periods, t he following medications are prohibited (for 
the randomized period, between Visit 1 through Visit 3; for the open-label period, between Visit 
3 and Visit 5) .   
o Investigational therapies  
o Chronic inhaled antibiotics other than cycled TISP (e.g., Cayston®, colistin). Chr onic 
treatment is defined as inhaled antibiotics prescribed as a maintenance therapy and not 
used temporarily to treat a pulmonary exacerbation.  
o Increase in chronic systemic corticosteroid dose beyond prednisone equivalent of 10 mg 
per day, or initiation of chronic systemic (oral or intravenous) corticosteroids  at any dose. 
Chronic use is defined as greater than 10 days continuous use.   
o New or increase in ibuprofen dose of greater than 800 mg total dose per 24 hours for 
more than 5 days  
o Nelfinavir, warfarin, haloperidol, or methadone  
7.4 Change in Medications or Therapies  
Subjects should receive all medication as clinically necessary, regardless of what impact this 
may have on the study.  
Maintaining a stable therapeutic regimen between Visit 1  and Visit 5 is desirable to minimize the 
risk of confounding.  Unless otherwise medically indicated, subjects not using these therapies 
should not be started on them after Visit 1  or at any time during the trial and subjects that have 
been using them chronically should be strongly encouraged to continue them throughout the 
entire study period ( through Visit 5).   
8 STUDY TREATMENTS  
8.1 Randomization  
At Visit 1, eligible subjects  will be  enrolled and randomized to study drug.   Study personnel at 
the investigative site will use the  Medidata® Rave and Balance™ systems to randomize each 
subject .  An adaptive randomization (dynamic allocation based on minimization31) will be 
employed. Subjects will be randomly assigned in a 1:1 ratio to azithromycin (500 mg three times 
per week ) or matched placebo. Randomization will be stratified by FEV 1 % predicted (25% -50%, 
>50% -75%, >75%), chronic oral azithromycin use for the past 30 days , inhaled tobramycin 
formulation (TIS or TIP), and site . The dynamic allocation algorithm seeks to optimize 
randomization balance by minimizing a weighted average of the marginal imbalance32 of  
treatment allocation for each factor and for the study overall.  A random element is added to the 
otherwise determin istic minimizat ion algorithm  to reduce allocation predictability by using a 
biased coin33 to include a chance of allocation to a treatment arm other than the arm that 
optimizes balance .  After data collection  at Visit 1 , subjects will be randomized to one of the two 
treatment groups .  To randomize a new subject, study personnel at the investigative site will 
complete the electronic CRF in the Medidata Rave system required to provide the stratification information and the subject  will then be assigned to a treatment group.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 29 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 8.2 Blinding  
Study treatment (azithromy cin or placebo) will be  assigned in a doubl e-blinded fashion.  
Subjects and site research staff will not know the treatment assigned, with the exception of the 
dispensing site pharmacist  or designee  and designated TDNCC personnel.    
The following study procedures will be in place to ensure double -blind administration of study 
treatments:   
 Randomization assignments will be stored in a secure database and appropriately 
protected and backed up   
 Access to the randomization code will be strictly controlled and limited to designated 
TDNCC study personnel  
 Test and control treatments will be manufactured to be identical in appearance and  taste-matched  
 Packaging and labeling of test and control treatments will be identical  
The study blind will be broken upon com pletion of the clinical study and after the study database 
has been locked and study results released. The site investigators will be provided with each 
subject’s treatment assignment following completion of data analysis.  
8.3 Unblinding Procedures  
During the study, the blind may be broken for individual subjects in emergencies when 
knowledge of the subject’s treatment group is necessary for further patient management or when 
the event meets the FDA expedited reporting requirements as a suspected adverse reacti on that is 
serious and unexpected (21 CFR 312.32(c)(1)(i)).  In those cases, knowledge of the treatment 
received is necessary for interpreting the event. Individual SAEs that are unexpected, deemed 
related to study drug, and confirmed by the Medical Monitor will be forwarded to the DSMB 
Chair within 7 business days . Additional information or data summaries may also be requested 
by the DSMB at this time.  
If the blind is broken and the subject is on study drug, a Safety Report will be sent to all 
participati ng investigators. Emergency unblinding procedures are provide d in the Study Manual .   
Refer to protocol section 11.2.1 Serious Adverse Experience Reporting.  
8.4 Formulation of Test and Control Products  
8.4.1 Formulation of Test Product  
Azithromycin 500 mg capsules  will be provided.   Over -encapsulated azithromycin tablets 
capsules  will be provided during the randomized period of the study.   
During the open-label extension period, commercially -available azithromycin 500 mg capsules  
(without over -encapsulation) will be  used.  
8.4.2 Formulation of Control Product  
Placebo capsules using the same materials used for azithromycin over -encapsulation will be 
provided.  The placebo will be appearance-matched.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 30 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 8.4.3 Packaging and Labeling  
Capsules  for the randomized period of the study will be provided in labeled bottles .  A six -week 
supply plus one extra (1 9) of capsules  will be included in each bottle .  One bottle will be 
supplied at Visit 1. 
If the subject enrolls in the open-label period, commercially -available azithromycin will be 
provided by the site pharmacy.  
8.5 Supply of Study Drug to the Site  
Study drug for the randomized period will be shipped to each site pharmacy.  The initial study 
drug shipment will be shipped after site approval to enroll (i.e., all required regulatory 
documentation has been received by the TDNCC and a contract has been executed). Subsequent 
study drug shipments will be made as needed.  
For the open-label period, sites will obtain their own supplies of commercially-available 
azithromycin capsules .  
8.5.1 Dosage/Dosage Regim en 
Randomized s tudy drug (azithromycin or placebo) and open-label azithromycin will be taken by 
mouth three times weekly during the following study periods:  
• Treatment  V1-V2: azithromycin or placebo without TISP:  14 days  
• Treatment  V2-V3: azithromycin or placebo with TISP : 28 days  
Subjects  participating in the optional open-label  extension:  
• Treatment V3 -V4: azithromycin without  TISP:  28 days   
• Treatment V4 -V5: azithromycin with TISP  28 days  
8.5.2 Study Drug Preparation and Dispensing  
Appropriately trained site pers onnel will be responsible for dispensing study drug (includes the 
randomized period and open-label period) .  Study drug shall be dispensed and labeled in 
accordance with federal and local state Board of Pharmacy regulations.  Capsules  will be 
provided in l abeled bottles from the study pharmacy with instructions to take one capsule  three 
times weekly .  
If the subject enrolls in the open-label period, a n 8-week supply plus one extra (25) of 
commercially -available azithromycin tablets will be dispensed at Visit 3.  
8.5.3 Administration Instructions  
Study drug (azithromycin or placebo and open-label azithromycin ) should be taken by mouth 
with food and pancreatic enzymes (if clinically prescribed).   
It is recommended that the first dose be taken at the Visit 1 to ens ure that the subject is able to 
swallow the capsule.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 31 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 8.5.4  Storage   
Study drug (azithromycin or placebo and open-label azithromycin)  should be stored by the study 
site at controlled room temperature, 15 to 30 ºC (59 to 86 ºF) in a secure area under restri cted 
access. If the temperature of study drug storage in the clinic/pharmacy exceeds or falls below this 
range, this should be reported to the Sponsor or designee.  
Subjec ts will be instructed to store study drug ( azithromycin or placebo and open-label 
azithromycin) in original packaging at room temperature.   
8.6 Dose Modifications  
8.6.1 Due to Toxicity  
If a study subject has moderate to severe toxicity (refer to Study Manual) , the following schedule 
for dosage adjustment can be made at the discretion of the site investigator:  
• If a study subject receiving study drug three times weekly  (TIW) experiences drug-
related toxicity, the dosing INTERVAL of the study drug will be extended to two times 
weekly ( BIW ; e.g., Monday and Thursday)  
• If a study subject does not tolerate  receiving study drug BIW, the subject should be 
permanently discontinued from study drug due to intolerance.  
Dose can return to TIW at the discretion of the  site investigator.  
8.6.2 Due to Treatment with Antibiotics  – Temporary Discontinuation of Study Drug  
Study drug should be temporarily discontinued for subjects prescribed macrolide antibiotics . 
Study drug may be temporarily discontinued at the discretion of the treating clinician during 
acute treatment with other medications (e.g. , additional antibiotics or drugs believed to increase 
QT prolongation).  
Regardless of study drug use, subjects should be encouraged to complete all study visits . 
8.6.3 Missed Doses  
Missed doses may be made up as long as they are not taken within 24 hours of the  next 
scheduled dose.  
8.7 Study Drug Accountability  
Study drug (azithromycin or placebo  and open-label azithromycin ) dispensed to subjects will be 
counted as noted in the Schedule of Events .  Study drug distribution will be recorded, including 
study drug identifier  (randomized period) , date, quantity, and subject ID.  
8.8 Measures of Treatment Compliance  
Subject daily diaries recording study drug and TISP  use will be reviewed and the number of 
doses taken will be recorded throughout the study.   Subjects will be asked to bring study drug 
bottles and the diary to each study visit and the number of study drug capsules  remaining will be 
compared with the number ideally taken.  Subjects will be questioned at each visit about missed 
or extra doses of study drug, open-label azithrom ycin, and/ or TISP.  Treatment compliance for 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 32 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 study drug will be based on the number of doses reported taken by the subject , with 
consideration of drug returns . 
8.9 Standard of Care Treatment with TISP  
Subjects will not be allowed to change from inhaled tobramycin solution to inhaled tobramycin 
powder (i.e. , TOBI® Podhaler) or vice versa while enrolled in the study.  Either tobramycin 
delivery mechanism will be allowed but subjects must be stable on one delivery mechanism, 
either solution or dry powder, for one or more  on/off c ycles (i.e., 8 weeks) prior to Visit 1.   
8.9.1 Administration Instructions  
If the subject is using i nhaled tobramycin solution, inhaled tobramycin will be administered as 
per the manufacturer’s instructions (e.g., 300 mg in 4 or 5 mL solution, nebulized and inhaled 
twice daily using a device approved by the drug manufacturer ). Tobramycin solution should be 
nebulized with a n approved nebulizer and air compressor without mixing or diluting with other 
solutions, according to manufacturer instructions.    
If the subj ect is using inhaled tobramycin powder , the TOBI Podhaler will be  administered as per 
the manufacturer’s instructions (e.g., 4 dry powder capsules inhaled twice daily using the 
supplied device ).  
Ideally, tobramycin should be inhaled twice daily following  airway clearance.  Airway clearance 
includes any inhaled bronchodilators, mucolytics (e.g. , DNase, hypertonic saline), and 
mechanical clearance devices (e.g. , Vest, acapella, hand percussion).  If airway clearance is not 
clinically recommended at least twi ce daily , then tobramycin should be inhaled following the 
single airway clearance session and again each day without airway clearance.  
Tobramycin should be stored refrigerated per manufacturer ’s instructions.   
9 STUDY PROCEDURES AND GUIDELINES  
The procedure s described below will be performed at the visits noted in the Schedule of Events 
(Appendix 1) and in Section 10. 
Prior to conducting any study-related activities, written informed consent and the Health Insurance Portability and Accountability Act (HIPAA)  authorization must be signed and dated 
by the subject or subject’s legal representative.  If appropriate, assent must also be obtained prior to conducting any study-related activities.  
9.1 Clinical Assessments  
9.1.1 Concomitant Medications  
All concomitant medicatio n and concurrent therapies will be documented as noted in the 
Schedule of Events.  Dose, route, unit, frequency of administration, indication for administration 
and dates of medication will be captured.    
9.1.2 Demographics and CFF Registry ID  
Demographic inform ation (date of birth, sex, race) will be recorded at Visit1 . CF Registry ID 
number will be recorded for participating CF subjects  who provide optional consent . 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 33 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 9.1.3 Medical History  
Relevant medical history, including history of current disease, other pertinent  respiratory history, 
and information regarding underlying diseases will be recorded.   Previous use of azithromycin 
and inhaled tobramycin will also be collected.  
9.1.4 CF Diagnosis  
Diagnosis date and sweat chloride test, CF genotype, and transepithelial nasal potential 
difference test result will be recorded  as available.  
9.1.5 Physical Examination  
A complete or abbreviated physical examination will be performed by a licensed professional 
(MD, NP, RN, PA) as noted in the Schedule of Events.  The abbreviated exam inc ludes 
respiratory, cardiovascular, and abdominal assessments.    
After the initial exam at Visit 1 , new clinically significant , abnormal physical exam findings 
must be documented as AEs.  
9.1.6 Weight and Height   
Weight will be measured on the same scale and recorded as noted in the Schedule of Events. 
Adults and children may remain in clothes (without shoes). A standing height will be measured 
and recorded as noted in the Schedule of Events .   
Note that accurate height measurements will significantly improve the  data quality, as this is 
incorporated into equations used to derive  the FEV 1% of predicted based on a reference 
population.  
9.1.7 Vital Signs  
Resting (minimum of 5 minutes) measurements of body temperature, blood pressure, pulse and 
respirations will be perform ed and recorded as noted in the Schedule of Events.  
9.1.8 Spirome try  
Spirometry will be performed at as noted in the Schedule of Events and in accordance with the 
current American Thoracic Society recommendations for the performance and interpretation of 
tests.  
Subjects should be encouraged to perform the same airway clearance routine and inhaled 
bronchodilators prior to each study visit.  Additional instructions for study personnel will be 
provided in the Study Manual.  
9.1.9 Re spiratory Culture  
If the patient does not have sufficient culture history to assess eligibility, a respiratory culture 
may be collected prior to randomization. If the respiratory culture is positive, the remaining Visit 
1 procedures and randomization will be conducted at a subsequent  visit.    
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 34 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 9.1.10  Subject Questionnaire: CFRSD-CRISS  
The subjects will be given a CF specific symptom diary called the CFRSD -CRISS  as noted in the 
Schedule of Events . This diary  includes 8 questions and takes less than 5 minutes to complete. 
The CFRSD -CRISS  should be admini stered at the beginning of each visit.  
9.1.11  Subject Questionnaire: Cystic Fibrosis Questionnaire -Revised (CFQ -R) 
The CFQ -R is a patient reported quality of life instrument, regarding symptoms and mood over 
the preceding 2 weeks.  The age appropriate  version of t he CFQ -R will be completed at the 
beginning of each visit as noted in the Schedule of Events by the subject . Completion should 
take less than 5 minutes.   
9.1.12  Subject Diary  
Subjects will be requested to complete a daily diary to document daily dose of study drug 
treatment s and TISP treatments , and to record changes in concomitant medications and 
symptoms through the end of the study. The diary will be dispensed and reviewed as noted in the 
Schedule of Events.  
9.1.13  Electrocardiogram (ECG)  
Standard 12-lead ECG tracin g will be obtained as noted in the Schedule of Events . ECG is only 
needed for  an acute visit if the subject has a cardiovascular -related AE or will no longer be 
participating in the study.  
Testing will be conducted and reviewed at the site by trained personnel with experience 
interpreting electrocardiograms.   Any test results of clinical concern, should be reported to the 
Medical Monitor to determine follow up actions as described below.   
Testing will be performed using an ECG machine that automatically ca lculates the heart rate and 
measures PR, QRS, QT, and QTc intervals.  All tests will be measured in Lead  II. 
Abnormal results at the time of follow -up testing are defined as a QTc >500 msec , or an increase 
in QTc of ≥60 ms ec.  It is recommended that testing be repeated after 10 minutes for any ECG s 
that meet the protocol  definition  for abnormal.  If test results are confirmed, subject s will be 
instructed to stop study drug or open-label azithromycin and the site inves tigator  will continue to 
observe the subject  for clinical signs of arrhythmia (specifically torsades de pointes).    
The ECG tracing will be collected for additional safety review.   
9.1.14  Signs and Symptoms Evaluation  
When a subject initiates a new IV, oral or inhaled antibiotic, the presence of specific signs and 
symptoms will be assessed and documented.   These data will be used to determine the incidence 
of a protocol defined pulmonary exacerbation based on the definition in Appendix 2.  
9.1.15  Adverse Events  
Informa tion regarding occurrence of AEs will be captured throughout  each subject’s study 
participation, starting after the first dose of study drug and ending once the subject has 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 35 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 terminated from  the study. D uration (start and stop dates),  grade , seriousness, out come, treatment 
and relation to study participation will be recorded on the CRF.  
9.2 Clinical Laboratory Measurements  
9.2.1 Pregnancy Test  
Urine or blood (approximately 2 cc) will be collected from females who are of childbearing 
potential for a pregnancy test as noted in the Schedule of Events and tested by the site  according 
to site standard procedures.  
9.2.2  Sputum Collection for Microbiological and Host Response Analysis   
Expectorated sputum will be collected from subjects who are able to produce sputum as note d in 
the Schedule of Events.  The samples collected will be stored frozen at -70 to -80ºC at the site 
and batch shipped as instructed by the Therapeutics Development Network Coordinating Center 
(TDNCC).  Instructions for specimen collection, processing, st orage and shipping of samples 
will be provided in the Study Laboratory Manual.  Processed aliquots will be banked for future 
analysis .   
10 EVALUATIONS BY VISIT  
Randomized Period 
10.1 Visit  1 – Day -14  
*A respiratory culture may be obtained prior to randomization to confirm eligibilit y criteria #4.  
If a respiratory culture is needed, the remaining Visit 1 procedures should be completed after 
confirming positive Pa  culture results.  
1. Review the study with the subject (subject’s legal representative) and obtain writ ten 
informed consent and HIPAA authorization and assent, if appropriate.  
2. Assign the subject a unique study number.  
3. If there is not a  recent respiratory culture  available, obtain culture to confirm eligibility:    
• Review culture results.  
• If Pa positive and m eets criteria #4, schedule subsequent  visit to complete 
remaining Visit 1 procedures.  
• If Pa negative, record as Screen Fail.   
4. Review and record previous use of azithromycin and inhaled tobramycin.  
5. Record demographics and CFF Registry ID, if consent obtained.   
6. Record medical history, including a history of CF  diagnosis  and date. 
7. Record concomitant medications.  
8. Administer PRO questionnaires (CFRSD -CRISS  and CFQ -R).  
9. Perform a complete physical examination.  
10. Measure and record height and weight.  
11. Obtain and re cord vital signs.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 36 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 12. Perform and record spirometry.  
13. Collect blood or urine for pregnancy test (if female of child-bearing potential).  
14. Obtain resting ECG . 
15. If able to expectorate sputum, collect expectorated sputum .    
16. Confirm subject eligibility.  
17. Randomize to study drug.  
18. Dispense study drug.   
19. Review study drug dose and schedule with subject.  
20. Provide subject diary and instruct ions for completion.  
21. Remind subject to NOT  use inhaled tobramycin between this day and Visit 2.   
22. Instruct subject to bring study drug bottle , any remaining capsules,  and diary  to Visit 2. 
23. Schedule subject for Visit 2.   
10.2 Visit 2 - Day 0 (visit window -2/+4 days)  
1. Administer PRO questionnaires (CFRSD -CRISS  and CFQ -R).  
2. Review subject diary.  
3. Perform pill count on returned study drug.  
4. Record a ny AEs.  
5. Record changes to concomitant medications.   If a new IV, oral or inhaled antibiotic was 
prescribed, ensure that a Signs and Symptoms form was completed.  
6. Perform an abbreviated physical examination.  
7. Measure and record height and weight.  
8. Obtain and record vital signs.  
9. Perform and record spirometry.  
10. If able to expectorate sputum, collect expectorated sputum .    
11. Provide subject diary.   
12. Review inhaled tobramycin schedule  and remind subject to take TISP between Visits 2 and 
3. 
13. Instruct subject to bring study drug bottle , any remaining capsules , and diary to Visit 3. 
14. Schedule subject for Visit 3.  Visit 3 should coincide with completion of approximately 4 
weeks use of inhaled tobramycin combined with study drug.  
End of Randomized Period and Start of Open-Label Period  
10.3 Visit 3 – Day 28 (visit window -2/+4 days ), W eek 4  
1. Administer PRO questionnaires (CFRSD -CRISS and CFQ -R).  
2. Review subject diary.  
3. Perform pill count on returned study drug.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 37 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 4. Record TISP  use. 
5. Record any AEs . 
6. Record changes to concomitant medicat ions. If a new IV, oral or inhaled antibiotic was 
prescribed, ensure that a Signs and Symptoms form was completed.  
7. Perform abbreviated physical examination.  
8. Measure and record height and weight.  
9. Obtain and record vital signs.  
10. Perform and record spirometry.  
11. Obtain resting ECG . 
12. If able to expectorate sputum, collect expectorated sputum . 
Visit 3: Additional procedures f or subjects enrolling in the o pen-l abel extension 
13. Assess subject eligibility for open-label  extension  
14. Review the open-label extension period of the study with the subject (subject’s legal 
representative) and obtain written informed consent and HIPAA authorization and assent, 
if appropriate.  
15. Dispense open-label azithromycin.   
16. Provide subject  diary .   
17. Remind subject to NOT  use inhaled tobramycin between this day and Visit 4.   
18. Instruct to bring the azithromycin bottle, any remaining tablets , and diary to Visit 4. 
19. Schedule subject for Visit 4.  
Open-Label Period  
10.4 Visit 4 – Day 56 (visit window +/- 4 days) , Open-La bel W eek 4  
1. Administer PRO questionnai res (CFRSD -CRISS and CFQ -R).  
2. Review subject diary.  
3. Perform pill count on returned azithromycin.  
4. Record any AEs .  
5. Record changes to concomitant medications.  If a new IV, oral or inhaled antibiotic was 
prescribed, ensure that a Signs and Symptoms form was completed.  
6. Perform abbreviated physical examination.  
7. Measure and record height and weight.  
8. Obtain and record vital signs.  
9. Perform and record spirometry.   
10. If able to expectorate sputum, collect expectorated sputum .  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 38 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 11. Provide subject diary.   
12. Instruct subject to bring the azithromycin bottle, any remaining tablets , and diary to    
Visit 5. 
13. Review inhaled tobramycin schedule  and remind subject to take TISP between Visits 4 
and 5.  
14. Schedule subject for Visit 5. 
10.5 Visit 5 - Day 84 (visit window +/- 4 days) , Open-Labe l W eek 8 
1. Administer PRO questionnaires ( CFRSD -CRISS and CFQ -R  
2. Review subject diary.  
3. Perform pill count on returned azithromycin.  
4. Record TISP use.  
5. Record any AEs .  
6. Record changes to concomitant medications.  If a new IV, oral or inhaled antibiotic was 
prescribed, ensure that a Signs and Symptoms form was completed.  
7. Perform abbreviated physical examination.  
8. Measure and record height and weight.  
9. Obtain and record vital signs.  
10. Perform and record spirometry.  
11. Obtain resting ECG . 
12. If able to expectorate sputum, collect expectorated sputum .  
13. Instruct subject that study participation is complete and to use medications according to 
instructions from clinical care providers.  
10.6 Unscheduled*  or Early  Discontinuation of Study Drug or Study Participation Visit  
*An Unschedule d Visit may be conducted as a study visit when, in the opinion of the site 
investigator, safety follow up is required as a result of a possible study-related procedure or study 
drug-related event.   
1. Administer PRO questionnaires ( CFRSD -CRISS and CFQ -R).  
2. Review subject diary.  
3. Perform pill count on returned study drug (if during randomized period) or azithromycin 
(if during open-label period) . 
4. Record any AEs .  
5. Record changes to concomitant medications.  If a new IV, oral or inhaled antibiotic was 
prescribed,  ensure that a Signs and Symptoms form was completed.  
6. Perform complete physical examination.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 39 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 7. Measure and record height and weight.  
8. Obtain and record vital signs.  
9. Perform and record spirometry.  
10. Obtain resting ECG , if appropriate (see footnote  b in Table for  Schedule of E vents) . 
11. If able to expectorate sputum, collect expectorated sputum . 
11 ADVERSE EXPERIENCE REPORTING AND DOCUMENTATION  
11.1 Adverse Events  
An AE is any untoward medical occurrence in a clinical investigation of a patient administered a 
pharmaceutical product and that does not necessarily have a causal relationship with the 
treatment.  An AE is therefore any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom or disease temporally  associated with the administration of an 
investigational product, whether or not related to that investigational product.  An unexpected AE is one of a type not identified in nature, severity, or frequency in the current Prescribing or 
Product Information or of greater severity or frequency than expected based on the information 
in the Prescribing or Product Information.  
The site investigator will probe, via discussion with the subject, for the occurrence of AEs during 
each subject visit and record the information in the site’s source documents.  Adverse events will 
be recorded in the subject CRF.   
AE Severity  
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4.0, as modified for CF, should be used to assess and grade AE severity, including 
laboratory a bnormalities judged to be clinically significant. The modified criteria can be found in 
the Study Reference Binder .  If the experience is not covered in the modified criteria, the 
guidelines shown in Table 1  below should be used to grade severity.  It should be pointed out 
that the term “severe” is a measure of intensity and that a severe AE is not necessarily serious.  
Table 1.  AE Se ve rity Grading  
Severity (Toxicity Grade) Description  
Mild (1) Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 
Moderate (2)   Moderate; minimal, local or noninvasive intervention indicated; 
limiting age -appropriate Instrumental activities of daily living (e .g., 
preparing meals, using the telephone, managing money)  
Severe (3)   Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (e.g., bathing, 
dressing, feeding self, using toilet, taking medications)  
Life-threatening (4)  Life-threatening consequences; urgent intervention indicated  
Death (5)  Death related to AE  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 40 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
  
AE Relationship to Study Drug  
The relationship of an AE to t he study drug (azithromycin or placebo for the randomized period, 
azithromycin for the open-label period)  should be assessed using the following the guidelines in 
Table 2 . 
Table 2.  AE Relat ionship to Study Drug  
Relationship 
to Drug  Comment  
Definitely  Previously known toxicity of agent; or an event that follows a reasonable 
temporal sequence from administration of the drug; that follows a known or 
expected response pattern to the suspected drug; that is confirmed by stopping or 
reducing the dosage of the drug; and that is not explained by any other 
reasonable hypothesis.  
Probably  An event that follows a reasonable temporal sequence from administration of the 
drug; that follows a known or expected response pattern to the suspected drug; 
that is confirmed by stopping or reducing the dosage of the drug; and that is 
unlikely to be explained by the known characteristics of the subject’s clinical 
state or by other interventions.  
Possibly  An event that follows a reasonable temporal sequence from administration of the 
drug; that follows a known or expected response pattern to that suspected drug; 
but that could readily have been produced by a number of other factors.  
Unrelated  An event that can be d etermined with certainty to have no relationship to the 
study drug.  
11.2 Serious Adverse Experiences (SAE)  
An SAE is defined as any AE occurring at any dose that results in any of the following 
outcomes:  
• death  
• a life-threatening adverse experience 
• inpatient hospitalization or prolongation of existing hospitalization 
• a persistent or significant disability/incapacity 
• a congenital anomaly/birth defect  
Other important medical events may also be considered an SAE when, based on appropriate medical judgment, they je opardize the subject or require intervention to prevent one of the 
outcomes listed.  
11.2.1  Serious Adverse Experience Reporting  
Study sites will document all SAEs that occur (whether or not related to study drug) on an SAE 
Report Form.  The collection period for  all SAEs will begin after informed consent is obtained 
and end after procedures for the final study visit have been completed.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 41 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 All SAE Report Forms will be reviewed by the site investigator and sent to the TDNCC within 
one business day of the site learning of the event.  Sites will send the SAE report by either:  
 Email (scanned copy) to: cfsaesfacsys@seattlechildrens.org  
 TDNCC SAE Fax: (206) 985-3278 
The site will notify the Medical Monitor  of additional information or follow -up to an initial SAE 
Report as soon as relevant information is available.  The Medical Monitor may request additional 
information related to the SAE.  Follow -up information is reported on an SAE Report Form.  
In accordance with the  standard operating procedures and policies of the local Institutional 
Review Board (IRB), the site investigator will report SAEs to the IRB.   
11.3 Medical Monitoring  
The TDNCC Medical Monitoring Group should be contacted directly at this  number to report 
medical concerns or questions regarding safety.  
  (800) 341-0961 
The TDNCC Medical Monitoring Group will serve as the independent Medical Monitor s for this 
study.  AEs and SAEs will be collected and organized by the TDNCC  and provided to the 
TDNCC Medical Monit oring Group for review in a timely manner. The TDNCC Medical 
Monitoring Group will communicate with the independent DSMB at a predetermined schedule, 
and additionally as warranted.  
12 DISCONTINUATION AND REPLACEMENT OF SUBJECTS  
12.1 Early Permanent Discontinuation of Study Treatment  
A subject may be permanently discontinued from study treatment at any time if the subject, the 
investigator, or the Sponsor -Investigator  feels that it is not in the subject’s best interest to 
continue.  The following is a list of possi ble reasons for early permanent discontinuation of study 
treatment:  
 Subject or subject’s legal representative decision  
 Adverse event, including pulmonary exacerbation  
 Protocol violation  
 Death  
If a subject is discontinued from treatment due to an AE, the subject will be followed and treated 
by the site investigator until the abnormal parameter or symptom has resolved or stabilized.   
All subjects who permanently discontinue study treatment early should come in for an early 
discontinuation of study treatme nt visit as soon as possible  (see Appendix 1)  and then should be 
encouraged to complete all remaining scheduled visits and procedures.  
Refer to Section 8.6.2 for temporary discontinuation of study drug.  
12.2 Early Withdrawal of Subjects from the Study  
All subjects are free to withdraw from participation at any time, for any reason, specified or 
unspecified, and without prejudice.  This may include subjects who withdraw from study 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 42 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 treatment early and who decline to continue to come in for remaining follow -up vis its or it may 
include subjects who completed treatment and decline to come in for remaining follow up visits.   
Reasonable attempts will be made by the investigator to provide a reason for early subject 
withdrawals.   The reason for the subject’s early withdrawal from the study will be specified in 
the subject’s source documents.   Subjects who withdraw early from the study should be 
encouraged to come in for a final early study withdrawal visit (and the procedures to be followed 
would include those for an ea rly discontinuation of study drug visit – see Appendix 1).   
12.3 Replacement of Subjects  
 Subjects who withdraw from the study will not be replaced.   
13 PROTOCOL VIOLATIONS  
A protocol violation occurs when the subject, investigator, or the Sponsor fails to adher e to 
significant protocol requirements affecting the inclusion, exclusion, subject safety and primary 
endpoint criteria.  Protocol violations for this study include, but are not limited to, the following:  
 Failure to meet eligibilit y  criteria  
 Use of a prohi bited concomitant medication. This includes the use of conditionally 
allowed medications without meeting the criteria to use these medications (e.g. 
Temporarily stopping study drug or open-label azithromycin).  
 Failure to obtain spirometry at Visit s 1-3 
Failure to comply with Good Clinical Practice (GCP) guidelines will also result in a protocol 
violation. The Sponsor -Investigator  will determine if a protocol violation should result in early 
discontinuation of study treatment for a subject.  
When a protocol violation occurs, it will be discussed with the investigator and a Protocol 
Violation Form detailing the violation will be generated. This form will be signed by a Sponsor representative and the site investigator. A copy of the form will be filed in the sit e’s regulatory 
binder and in the Sponsor’s files. The site will report the violation to their IRB in accordance 
with their IRB reporting requirements.  
14 DATA SAFETY MONITORING  
A Data Safety Monitoring Board (DSMB) will review comprehensive interim enrollment , safety, 
and efficacy data reports when approximately 50% and 75% of patients have completed the 
randomized period of the study.  Regular reporting frequency to the DSMB is detailed in the 
DSMB charter.    A priori interim stopping rules for futility and ef ficacy/harm with respect to the 
primary endpoint are outlined in the DSMB charter. SAEs  will be monitored by the committee 
on an ongoing basis throughout the study.   Further details are included in the DSMB charter . 
15 STATISTICAL METHODS AND CONSIDERATIONS  
A detailed statistical analysis plan will be written that will describe all analyses that  will be 
generated f or this study. All analyses will be performed using SAS
® (SAS Institute, Inc., Cary, 
NC, USA) or R (R Foundation for Statistical Computing, Vienna, Austria).  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 43 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 15.1 Data Sets Analyzed  
All analyses will be performed using a  modif ied intent -to-treat ( m-ITT) population, which is 
defined as all randomized subjects  who received at least one dose of study drug. Subjects  who 
are discontinued from study drug tempor arily or permanently are encouraged to complete all 
remaining study visits and will remain in the analyses population according to ITT.  The primary 
efficacy analyses will be repeated in the per -protocol population, which is defined as subjects  
having completed ≥80% of doses (azithromycin and or placebo) and who did not require the use 
of acute antibiotics  or steroids . All tests will be two -sided and evaluated at a 0.05 level of 
significance.  
15.2 Demographic and Baseline Characteristics  
Baseline demographic s and clinical characteristics recorded at Visit 1 will be summarized 
including (but not limited to) age, sex, CFTR genotype, race, height, weight, BMI, FEV 1% 
predicted, Pa bacterial density, delivery method of chronic tobramycin ( i.e., dry powdered or 
inhale d), and use of other chronic medications ( e.g., CFTR modulators,  inhaled dornase alfa and 
hypertonic saline).  
15.3 Analysis of Primary Endpoint  
The primary endpoint will be the difference between the azithromycin and placebo treatment 
groups in the relative change from Visit 1  to Visit 3  in FEV 1 (liters).  The primary endpoint will 
be compared between treatment groups using linear regression adjusted for randomization strata. 
Least squares means and the treatment effect for the relative  change will be presented  as well as 
corresponding 95% confidence interval and p-values. The p-values will be evaluated against a 
two-sided 0.05 level of significance.  
Additional  secondary analysis may be performed to adjust for potential baseline confounders 
including age, sex, and baseline FEV 1.  Sensitivity analyses of the primary endpoint will be 
performed using the per -protocol population.  Additional sensitivity analyses will be performed 
to address missing data. Specifically, the least favorable treatment arm imputation met hod will 
be used which imputes that missing value with the mean change from the treatment arm with the 
worst change in the observed case analysis.  Further details regarding the handling of missing 
data will be provided in the statistical analysis plan.  
15.4 Analysis of Secondary Endpoints  
Randomized Period  
Descriptive analyses and graphical displays will be used to summarize all secondary endpoints.  Endpoints will be compared between the azithromycin and placebo treatment groups from Visit 
1 through Visit 3.  
All reported SAEs and AEs will be coded using MedDRA and grouped by body system.  The 
incidence of AEs (including emergent abnormal QTc parameters) between the azithromycin and 
placebo treatment groups will  be tabulated by seriousness, severity, and relationship to study 
drug.  Rates of (S)AEs by System Organ Class (SOC) will also be summarized.  Poisson 
regression modeling will be used to derive rate ratios and corresponding 95% confidence and to 
compare gr oups using a using a two-sided 0.05 level test.  Histogram s showing the frequency of 
the number of (S)AEs in each treatment group will be included.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 44 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 The proportion of subjects permanently or temporarily discontinuing study drug will also be 
tabulated by trea tment group.  Drug discontinuation events will be categorized as:  (1) 
Permanently discontinued study drug, (2) Permanently discontinued study drug and withdrew 
from study, and (3) Temporarily discontinued study drug.  Reason for permanent drug 
discontinua tion will be summarized.  C ompliance measures will be computed separately for the 
TISP and azithromycin /placebo therapies.   
Continuous secondary endpoints including changes in sputum bacterial density, weight, patient -
reported quality of life  (as measured by scales derived from the CFQ -R and CFRSD -CRISS),  
and pulmonary function (FEV 1 % predicted, FVC, and FEF 25%-75%) will be modeled similarly to 
the primary endpoint.  Predicted values for spirometry measures at each visit will be calculated using the Global Lung Initiative reference equations.
30  Least squares means and the treatment 
effect for the change for each secondary endpoint from Visit 1  to Visit 3 will be p resented as 
well as corresponding 95% confidence intervals and p-values.  The relative change in 
FEV 1(liters) during administration of TISP from Visit 2 to Visit 3 will b e analyzed in a similar 
manner . 
Event rates  for hospitalization , pulmonary exacerbations,  intravenous antibiotic usage, inhaled 
antibiotic usage, and oral antibiotic usage from Visit 1  through Visit 3 will be descriptively 
summarized  and differences in the proportions  of subjects with an event  between the treatment 
groups will be estimated with accompanying 95% confidence intervals . Event rates will be 
compared between treatment groups using Poisson regression.  
Open-Label Period  
Selected endpoints obtained during the randomized period will continue to be collected during 
the open-label  perio d of the study.  The change in lung function during the open-label  period will 
be modeled among placebo subjects , and compared to both the change observed in this group 
during administration of TISP  in the randomized trial and the change observed in the ac tive 
group during administration of TISP  in the randomized trial.  Moreover , among those 
randomized to azithromycin, difference s in the lung function between the randomized and open-
label periods of TISP administration will be compared. Similarly, other en dpoints measured in 
the open-label  period will be used to estimate longer term changes in response to azithromycin in 
the group randomized to azithromycin.  Data from the placebo subjec ts who entered into the 
open-label period  will be used to compare resul ts with those observed during the randomized 
period of the trial .  Further details will be provided in the SAP that will be finalized prior to the 
first interim data analysis.   
15.5 Interim Analysis   
An independent data monitoring board (DSMB) will review comprehensive interim report s when 
approximately 50% and 75% of patients have completed the randomized period of the study.  
These interim report s will include an overview of enrollment , detailed summaries of SAEs, AEs, 
withdrawals, drug discontinuations, hospi talizations, protocol violations and other clinical safety 
endpoints . The primary endpoint and select  secondary endpoints  will be summarized as outlined 
in the statistical analysis plan.  Shoul d the DSMB consider stopping the trial based on the 
primary endpoint, they will be guided by a priori  interim stopping rules for futility and 
efficacy/harm outlined in the DSMB charter. Regular reporting frequency to the DSMB is 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 45 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 detailed in the DSMB charter.  SAEs will be monitored by the committee on an ongoing basis 
throughout the study.  
15.6 Sample Size  
The primary endpoint is the difference between the azithromycin and placebo treatment groups 
in the relative change from  Visit 1 to Visit 3 in FEV 1 (liters).   Data from prior published studies  
of similar duration  are avai lable to estimate sample size and power for the study including a 
randomized, placebo-controlled trial of azithromycin in individuals with CF chronically infected 
with Pa and a randomized, placebo controlled trial of aztreonam lysine similarly among those 
with chronic Pa.  These studies suggest a standard deviation of the relative change in FEV 1 
ranging from 10 to 16.  Based on these prior studies, we ant icipate the relative change in FEV 1 
from Visit 1 to Visit 3  to be -2%  in the azithromycin arm and +6.85%  in the placebo arm for an 
overall treatment effect of 8.65%.    A sample size of 110 provides 85% power to detect a 
treatment effect of 7.5% or greater assuming a standard deviation of 13.  110 subjects provides 
93% power to detect a treatment effect similar to what wa s observed in the preliminary data 
(8.65%)  assuming a standard deviation of 13.   It is noteworthy that the standard deviation from 
more rec ently completed studies CF studies have observed standard deviations in short term 
relative change in FEV (liters) ranging from 8-11, confirming our conservatism in the standard 
deviation estimate used for our sample size calculations.    Assuming a standa rd deviation of 11, 
a sample size of 110 provides 85% power to detect a treatment effect of 6.3% or greater in favor 
of the placebo group.  Figure 8 displays several scenarios for the statistical power we have to 
detect a range of differences in relative change in FEV 1 (L).    
  
Figure 8 .  Power to detect a range of differences in r elative change  in FEV 1 (L) for total 
sample size of 110 (55 per group)  assuming a two-sided 0.05  level t -test.  Curves (in ascending 
order) correspond to standard deviations of 15, 13, 11, 9, and 7.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 46 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 4 6 8 10 120.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0Total Sample Size Equal to 110
Detectable Treatment Effect (Relative Change   Power
Target Effect Size for the TEACH Trial
 
16 DATA COLLECTION, RET ENTION AND CLINICAL MONITORING  
16.1 Data Collection Instruments  
The investigator will prepare and maintain adequate and accurate source documents designed to 
record all observations and other pertinent data for each subject who signs informed consent.  
Study personnel at each site will enter data from source documents corresponding to a subject’s 
visit into the protocol -specific electronic CRF when the information corresponding to that visit is 
available.  Subjects will not be identified by name in the study database or on any study 
documents to be collected by the Sponsor (or designee), but will be identified by a subject 
number and initials.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 47 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 If a correction is required for a CRF, the  time and date stamps track the pers on entering or 
updating CRF data and create an electronic audit trail.   
The investigator is responsible for all information collected on subjects enrolled in this study.  
All data collected during the course of this study must be reviewed and verified for  completeness 
and accuracy by the investigator.   At the completion of the study, a copy of the CRF data will be 
provided to the site to be retained at the Investigator’s site.  
16.2 Data Management Procedures  
TDNCC utilizes Medidata Solutions, Inc. (Medidata) Ra ve for their EDC studies. The Medidata 
Rave EDC system is designed to be US Code of Federal Regulations (CFR) 21 Part 11 compliant 
with a robust audit trail system and electronic signature capabilities.  Study personnel at each site will enter data from a subject’s visit onto electronic CRF screens via a web browser.  Study 
subjects will not be identified by name in the study database or on any data capture screens, but 
will be identified by initials and a unique subject identification number.  Only study personnel at the individual sites will be able to link the study ID to the subject’s name.  The Data 
Management group of the TDNCC will be responsible for data processing, in accordance with 
procedural documentation.  Database lock will occur once quality a ssurance procedures have 
been completed.  All procedures for the handling and analysis of data will be conducted using 
good computing practices for the handling and analysis of data for clinical trials.   
16.3 Data Quality Control and Reporting  
After data have been entered into the study database, data validation checks will be applied on a 
regular basis. Queries are entered, tracked, and resolved through the EDC system directly.   The 
study database will be updated in accordance with the resolved queries. All changes to the study 
database will be documented in an audit trail.   
16.4 Security and Archival of Data  
The EDC system is hosted by Medidata; the data are stored at Medidata’s primary data center in 
Houston, Texas, with fail -safe data centers in New Jersey.  Data are regularly backed up by 
Medidata and stored with Iron Mountain.  
Medidata maintains 21 CFR Part 11-compliant electronic systems, with proce dures in place to 
safeguard against unauthorized acquisition of data.  Any authorized communication with the 
Medid ata servers at the Houston Data Center is conducted via SSL (128-bit) encryption.  Robust 
password procedures,  consistent with 21 Part 11, are in place.  Robust physical security 
procedures are in place at the Houston Data Center to prevent unauthorized pe rsonnel physical 
access to the server rooms.  EDC account access is maintained and monitored by the Biostatistics 
and Clinical Data Management group of the TDNCC.  
Other databases will be stored on Seattle Children’s servers and are safeguarded against 
unauthorized access by established security procedures.  Network accounts are password 
protected and maintained and monitored by the Seattle Children’s Information Technology 
group.  Data is backed up regularly according to the Information Services  group’s procedures.  
Note that there is an intention to make biospecimens and associated data available to 
investigators for future exploration. The biospecimens will be collected under IRB approval, 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 48 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 processed according to a rigorous standard operating procedure and stored at a central facility, 
with appropriate procedures to enable long term, stable storage. Researchers may apply, via a standardized process, for use of de -identified data and specimens for research purposes. 
Applications will undergo a scientific revi ew process administered through CFFT. When 
applying for use of data or specimens, the applicant must agree to: (1) use the data and specimens only for research purposes and to not make any attempts to try to identify any individual subject; (2) secure  the data and specimens using appropriate methods; and (3) destroy 
or return the data (and specimens) in accordance with the specimen/data use agreement after analyses are completed.  Before data or specimens will be released to an investigator, documentation of IRB exemption or approval from their institution must be provided to the 
CFFT.   
16.5 Availability and Retention of Investigational Records  
The investigator must make study data accessible to the monitor, other authorized representatives 
of the Sponsor (or de signee), IRB, and Regulatory Agency (e.g., FDA) inspectors upon request.  
A file for each subject must be maintained that includes the signed informed consent, Health 
Insurance Portability and Accountability Act (HIPAA) authorization and assent form (if 
applicable) and copies of all source documentation related to that subject.  The i nvestigator must 
ensure the reliability and availability of source documents from which the information on the 
CRF was derived.  
All study documents (e.g., patient files, signed informed consent forms, copies of CRFs, 
Essential Document and Study Reference Binders) must be kept secured for a period of two 
years following completion of the study.  There may be other circumstances for which the Sponsor is required to maintain study records and, therefore, the Sponsor should be contacted 
prior to removing study records for any reason.  
16.6 Monitoring  
By signing this protocol, the i nvestigator grants permission to the Sponsor (or designee) and 
appropriate regulatory authorities to conduct on-site monitoring and/or auditing of all appropriate 
study documentation, if needed . Monitoring visits may be conducted by representatives of the 
Sponsor according to the U.S. CFR 21 Part 312 to ensure investigator compliance to 21 CFR 
Parts 50, 56 and 312 and to GCP.   
16.7 Subject Confidentiality  
In order to maintain subject confidentiality, only a subject number and subject initials will 
identify all study subjects on CRFs and other documentation submitted to the Sponsor. If specific consent is given, the subject’s CFF patient registry number will also be collected. Additional 
subject confidentiality issues (if applicable) are covered in the Clinical Study Agreement.  
17 ADMINISTRATIVE, ETHICAL, REGULATORY CONS IDERATIONS  
The study will be conducted according to t he Declaration of Helsinki, Protection of Human 
Volunteers (21 CFR 50), Institutional Review Boards (21 CFR 56), and Obligations of Clinical 
Investigators (21 CFR 312).  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 49 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 To maintain confidentiality, all laboratory specimens, evaluation forms, reports and ot her records 
will be identified by a coded number and initials only.  Clinical information will not be released 
without written permission of the subject, except as necessary for monitoring by the FDA.  The 
investigator must also comply with all applicable privacy regulations (e.g., Health Insurance 
Portability and Accountability Act of 1996, EU Data Protection Directive 95/46/EC).  
17.1 Protocol Amendments  
Any amendment to the protocol will be written by the  Sponsor -Investigator  and agreed to by the 
study Steering Committee .  Protocol amendments cannot be implemented without prior written 
IRB approval except as necessary to eliminate immediate safety hazards to patients.  A protocol 
amendment intended to eliminate an apparent immediate hazard to patients may be im plemented 
immediately, provided the IRBs are notified within five working days.  
17.2 Institutional Review Boards  
The protocol and consent form will be reviewed and approved by the IRB of each participating 
center prior to study initiation.  SAEs  regardless of causality will be reported to the IRB in 
accordance with the standard operating procedures and policies of the IRB, and the i nvestigator 
will keep the IRB informed as to the progress of the study.  The i nvestigator will obtain 
assurance of IRB compliance w ith regulations.  
Any documents that the IRB may need to fulfill its responsibilities (such as protocol, protocol amendments, consent forms, information concerning patient recruitment, payment or compensation procedures, or other pertinent information) will  be submitted to the IRB.  The 
IRBs written unconditional approval of the study protocol and the informed consent form will be 
in the possession of the investigator before the study is initiated.  The IRB’s unconditional 
approval statement will be transmit ted by the investigator to the TDNCC  prior to the shipment of 
study supplies to the site.  This approval must refer to the study by exact protocol title and 
number and should identify the documents reviewed and the date of review.  
Protocol and/or informed consent modifications or changes may not be initiated without prior 
written IRB approval except when necessary to eliminate immediate hazards to the patients or 
when the change(s) involves only logistical or administrative aspects of the study.  Such 
modif ications will be submitted to the IRB/IEC and written verification that the modification 
was submitted and subsequently approved should be obtained.   
The IRB must be informed of revisions to other documents originally submitted for review; serious and/or unexpected adverse experiences occurring during the study in accordance with the 
standard operating procedures and policies of the IRB; new information that may affect 
adversely the safety of the patients of the conduct of the study; an annual update and/or request 
for re -approval; and when the study has been completed.  
17.3 Informed Consent Form  
Informed consent will be obtained in accordance with the Declaration of Helsinki, US Code of 
Federal Regulations for Protection of Human Subjects (21 CFR 50.25[a,b], C FR 50.27, and CFR 
Part 56, Subpart A), HIPAA, if applicable, and local regulations.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 50 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 The investigator will prepare the informed consent form, assent and HIPAA authorization and 
provide the documents to the Sponsor or designee for approval prior to submission to the IRB.  
The consent form generated by the i nvestigator must be acceptable to the Sponsor and be 
approved by the IRB.  The written consent document will embody the elements of informed 
consent as described in the US Code of Federal Regulations and wi ll also comply with local 
regulations. The investigator will send an IRB -approved copy of the Informed Consent Form to 
the Sponsor (or designee) for the study file.  
A properly executed, written, informed consent will be obtained from each subject prior to entering the subject into the trial.  Information should be given in both oral and written form and 
subjects must be given ample opportunity to inquire about details of the study.  If appropriate 
and required by the local IRB, assent from the subject will also be obtained.  If a subject is 
unable to sign the informed consent form and the HIPAA authorization, a legal representative 
may sign for the subject.   A copy of the signed consent form (and assent) will be given to the 
subject and the original will be  maintained with the subject’s records.  
During the course of the study, if modifications are made to the consent form that impact the 
subject, the subject will be re -consented as described above.  
17.4 Consent for Collection and Use of CFF Registry ID Number  
To facilitate possible future evaluation of retrospective and prospective information from all 
patients who screen for this study, consent will also be sought to collect the subject’s CFF Registry ID number at the screening visit.  The CFF Registry collects  data on all CF patients who 
consented to participate in the CFF Registry and who are followed at CFF -accredited care 
centers.  The registry data includes information from clinical encounters, hospitalizations courses 
of antibiotics, and year -end surveys.  Data also include microbiology results, spirometry results, 
CF genotype and other information. If specific consent is given to collect this number, the 
subject’s CF Registry ID number will be recorded in the CRF.  
17.5 Publications  
The preparation and submitta l for publication of manuscripts containing the study results shall be 
in accordance with a process determined by mutual written agreement among the study Sponsor 
and participating institutions.  The publication or presentation of any study results shall c omply 
with all applicable privacy laws, including, but not limited to, the Health Insurance Portability 
and Accountability Act of 1996.  
17.6 Investigator Responsibilities  
By signing the Agreement of Investigator form, the i nvestigator agrees to:  
1. Conduct the st udy in accordance with the protocol and only make changes after notifying 
the Sponsor (or designee), except when to protect the safety, rights or welfare of subjects.  
2. Personally conduct or supervise the study (or investigation).  
3. Ensure that the requirement s relating to obtaining informed consent and IRB review and 
approval meet federal guidelines, as stated in § 21 CFR, parts 50 and 56.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 51 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 4. Report to the Sponsor or designee any AEs that occur in the course of the study, in 
accordance with §21 CFR 312.64.  
5. Ensure  that all associates, colleagues and employees assisting in the conduct of the study are 
informed about their obligations in meeting the above commitments.  
6. Maintain adequate and accurate records in accordance with §21 CFR 312.62 and to make those records a vailable for inspection with the Sponsor (or designee).  
7. Ensure that an IRB that complies with the requirements of §21 CFR part 56 will be 
responsible for initial and continuing review and approval of the clinical study.  
8. Promptly report to the IRB and the S ponsor (or designee) all changes in the research activity 
and all unanticipated problems involving risks to subjects or others (to include amendments 
and IND safety reports).  
9. Seek IRB approval before any changes are made in the research study, except when necessary to eliminate hazards to the patients/subjects.  
10. Comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements listed in § 21 CFR part 312.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 52 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 18 REFERENCES  
 
1. 2013 Annua l Data Report; Cystic Fibrosis Foundation Patient Registry. 2014.  
2. Courtney JM, Bradley J, McCaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol. 
2007;42(6):525- 532. 
3. Lopes AJ, Mafort TT, de Sa Ferreira A, Santos de Castro MC, Cassia de Firmida M, de Andrade Marques E. Is the type 
of chronic pulmonary infection a determinant of lung function outcomes in adult patients w ith cystic fibrosis? Monaldi 
archives for chest disease 2012;77(3- 4):122 -128. 
4. Ruddy J, Emerson  J, Moss R, et al. Sputum tobramycin concentrations in cystic fibrosis patients with repeated 
administration of inhaled tobramycin. Journal of aerosol medicine and pulmonary drug delivery. 2013;26(2):69- 75. 
5. Lenoir G , Antypkin YG , Miano A, et al. Efficac y, safety, and local pharmacokinetics of highly concentrated nebulized 
tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatric drugs. 2007;9 S uppl 
1:11- 20. 
6. Vandyke RD, McPhail GL, Huang B, et al. Inhaled tobramycin effectively reduces FEV 1 decline in cystic fibrosis. An 
instrumental variables analysis. Annals of the American Thoracic Society. 2013;10(3):205 -212. 
7. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibro sis: A 
comparative efficacy trial. J Cyst Fibros. 2012.  
8. Ramsey BW PM, Quan JM, Otto KL, Montgomery AB, Williams -Warren J, Vasiljev -KM, Borowitz D, Bowman CM, 
Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. 
Cystic Fibrosis Inhaled Tobramycin S tudy G roup. N Engl J Med. 1999;340:23- 30. 
9. Mayer -Hamblett N, Rosenfeld M, Treggiari MM, et al. Standard care versus protocol based therapy for new onset 
Pseudomonas aeruginosa in cystic fibrosis . Pediatr Pulmonol. 2013.  
10. Saiman L, Marshall BC, Mayer -Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected 
with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749- 1756.  
11. Equi A, Balfour -Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a 
randomised, placebo -controlled crossover trial. Lancet. 2002;360(9338):978- 984. 
12. Ratjen F, Saiman L, Mayer -Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in patients 
with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest. 2012;142(5):1259- 1266.  
13. Verleden GM, Vanaudenaerde BM, Dupont LJ, VanRaemdonck DE. Azithromycin reduces airway neutrophilia and 
interleukin -8 in patients w it h bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174:566- 570. 
14. Ribeiro CM, Hurd H, Wu Y, et al. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, 
and cell cycle pathways in well -differentiated human air way epithelia. PLoS ONE. 2009;4(6):e5806.  
15. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti -inflammatory effects of azithromycin in cystic fibrosis 
airway epithelial cells. Biochem Biophys Res Commun. 2006;350:977 -982. 
16. Mogayzel PJ, Jr., Na ureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for 
maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680- 689. 
17. Nichols DP, Caceres S, Caverly L, et al. Effects of azithromycin in Pseudomonas ae ruginosa burn wound infect ion. The 
Journal of surgical research. 2013.  
18. Nichols DP, Caceres S, Caverly L, et al. Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. The Journal of surgical research. 2013;183(2):767- 776. 
19. Nick JA, Moskowitz SM, Chmiel JF, et al. Azithromycin May Antagonize Inhaled Tobramycin when Targeting 
Pseudomonas aeruginosa in Cystic Fibrosis. Annals of the American Thoracic Society. 2014.  
20. Caceres SM, Malcolm KC, Taylor -Cousar JL, et al. Enhanced in vitro f ormation and antibiotic resistance of 
nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob Agents 
Chemother. 2014;58(11):6851- 6860.  
21. Armour AD, S hankow sky HA, S w anson T, Lee J, Tredget EE. The impact of nosocomially -acquired resistant 
P seudomonas in a burn unit . J Trauma. 2007;63:164- 171. 
22. Dales L, Ferris W, Vandemheen K, Aaron SD. Combination antibiotic susceptibility of biofilm -grow n Burkholderia 
cepacia and Pseudomonas aeruginosa isolates from patie nts with pulmonary exacerbations of cytic fibrosis. Eur J Clin 
Microbiol Infect Dis. 2009;28(10):1275- 1279.  
23. Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R. Single and combination antibiotic susceptibilities 
of planktonic, adherent, and biofilm -grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic 
fibrosis. J Clin Microbiol. 2002;40:4172 -4179.  
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date: 11JUN2018  Page 53 of 56 
Protocol Template:  © CFFT TDN   Effective: 28 DEC 2012 
 24. McCoy KS , Quittner AL, Oermann CM, G ibson RL, Retsch- Bogart GZ, Montgomery AB. Inhaled aztreonam lysine 
for chronic a irway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921 -928. 
25. Wagener JS, Rasouliyan L, Vandevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating 
pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2012.  
26. Saiman L, Anstead M, Mayer -Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic 
fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303:1707- 1715.  
27. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J 
Med. 2012;366(20):1881 -1890.  
28. Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 
2013;368( 18):1704- 1712.  
29. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology. 
2004;37(5):400- 406. 
30. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG , Jr. Pulmonary function betw een 6 and 18 years of age. Pediatr  
Pulmonol. 1993;15(2):75- 88. 
31. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical 
trial. Biometrics. 1975;31(1):103- 115. 
32. Han B, Enas NH, McEntegart D. Randomization by minimization for  unbalanced treatment allocation. Stat. Med. 
2009;28(27):3329 -3346.  
33. Brow n S , Thorpe H, Haw kins K, Brow n J. Minimization- reducing predict abilit y for mult i -centre trials whilst retaining 
balance within centre. Stat. Med. 2005;24(24):3715- 3727.  
 
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date:  Page 54 of 56 
Protocol T emplate © CFFT TDN   Effective: 28 DEC  2012 19 APPENDIX 1 SCHEDULE OF EVEN TS 
 RANDOMIZED , PLACEBO -
CONTROLLED , DOUBLE BLIND  OVERLAP  OPEN-LABEL , FOLLOW -ON 
UNSCHEDULED /  
EARLY TERM  
VISIT f  VIS IT 1 * 
Day -14  
 VIS IT 2  
(Day 0) 
 (-2 to +4 days)  VISIT  3 
Day 28 
(-2 to +4 days)  VISIT 4EXT  
Day 56 
(± 4 days)  VIS IT 5 EXT  
Day 84 
(±4 days) 
Infor med Consen t X  Xe    
Respiratory Culture (as needed)  Xh      
Demographics  and M edical  History  X      
Complete  CFQ -R and CFRSD -CRISS  X X X X X X 
Complete  Physical  Exam  X     X 
Abbreviated  Physical  Exam   X X X X  
Height  X X X X X X 
Weight X X X X X X 
Vital  Signs  X X X X X X 
Spirometry  X X X X X X 
 Pregnancy  Test at site (Urine  or Serum) a X      
ECG  Testing  X  X  X X b 
Collect sputum for analysis  and banking  c X X X X X X 
Randomize to azithromycin or placebo X      
Dispense  azithromycin/placebo  dose and 
review dose schedule  X                 
Dispense open -label azithromycin and review 
dose schedule    Xe    
Provide Subject Diary X X Xe X   
Protocol TEAC H -IP-15 Confidential  
 
Version #:  4.0 Version Date:  Page 55 of 56 
Protocol T emplate © CFFT TDN   Effective: 28 DEC  2012  RANDOMIZED , PLACEBO -
CONTROLLED , DOUBLE BLIND  OVERLAP  OPEN-LABEL , FOLLOW -ON 
UNSCHEDULED /  
EARLY TERM  
VISIT f  VIS IT 1 * 
Day -14  
 VIS IT 2  
(Day 0) 
 (-2 to +4 days)  VISIT  3 
Day 28 
(-2 to +4 days)  VISIT 4EXT  
Day 56 
(± 4 days)  VIS IT 5 EXT  
Day 84 
(±4 days) 
Instruct  to hold use of inhaled  tobramycin for 
off-cycle until the next study visit X  Xe    
Concomitant  M edication  Review  X X X X X X 
Adverse  Events   X X X X X 
Review Subject Diary and pill count   X X X X X 
Record TISP  use    X  X X 
Review  inhaled  tobramycin schedule   X  X   
Assess eligibility for Open -label    Xe    
Signs an d Symptoms Assessment g Start  Stop  
Starte  Stop   
 
* If the patient does not have sufficient culture history to assess eligibility, a respiratory culture may be collected prior t o randomization.  If the respiratory 
culture is positive, the r emaining V isit 1 procedures and randomization will be conducted at a subsequent visit .   
      a     Only females  of child -bearing  potential  
b ECG is only required at an Unscheduled visit (if the subject has a cardiovascular related adverse event) or at an Early Termination Visit (when the subject 
permanently discontinues study drug or will no longer be participating in the study) 
c Expectorated sputum will be collected from subjects who are able to produce sputum  
e Perform only if rolling over into Open-L abel 
     f      Early termination includes early permanent discontinuation of study drug or early  study withdrawal . An Unscheduled Visit may be conducted as a study visit when, 
in the opinion of the site investigator, safety follow up is required as a res ult of a possible study -related procedure or study drug -related event.   
g Assessment only when a new antibiotic is prescribed during the study  
h     If there is not a r ecent respiratory culture available, obtain culture to confirm eligibility.   
Protocol TEACH -IP-15                                                                                                                  Confidential  
 
Version #:  4.0 Version Date:  Page 56 of 56 
Protocol T emplate © CFFT TDN   Ef fective: 28 DEC 2012 20 APPENDIX  2 PROTOCOL DEFINED PUL MONARY EXACERBATION 
DEFINITION 
 
The presence of a pulmonary exacerbation is established by the following:  
(1) One of the major criteria alone  
             or  
(2) Two of the minor signs/symptoms and fulfillment of symptom duration   
 
Major Crite ria:  (One finding alone establishes the presence of a pulmonary exacerbation)  
(1) Absolute decrease in FEV 1 %predicted of ≥10%  
(2) Oxygen saturation <90% on room air or  absolute decrease of ≥  5%  
(3) New lobar infiltrate(s) or atelectasi(e)s on chest  radiograph 
(4) Hemoptysis (more than streaks on more than one occasion in past week)  
 
Minor Signs/Symptoms:  (Two minor signs/symptoms are required in the absence of m ajor  
criteria. If at least 2 minor signs/symptoms are present , at least one needs to be 3 or more 
days in duration to meet the pulmonary exacerbation definition ) 
(1) Increased work of breathing or respiratory rate  
(2) New or increased adventitial sounds on lung exam  
(3) Weight loss ≥5% of body weight or decrease across 1 major percentile in we ight 
percentile for age in past 6 months  
(4) Increased cough 
(5) Decreased exercise tolerance or level of activity  
(6) Increased chest congestion or change in sputum  
 
 
 
 
 
 
 
  